Plasmodium	B-DS
malariae	I-DS
Infection	I-DS
Associated	O
with	O
a	O
High	O
Burden	O
of	O
Anemia	B-DS
:	O
A	O
Hospital	O
-	O
Based	O
Surveillance	O
Study	O

The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
SL	O
NMD	O
NMA	O
JRP	O
RNP	O
.	O

Performed	O
the	O
experiments	O
:	O
DAL	O
EK	O
PS	O
JRP	O
.	O

Analyzed	O
the	O
data	O
:	O
SL	O
NMD	O
JAS	O
RNP	O
.	O

Wrote	O
the	O
paper	O
:	O
SL	O
NMD	O
JAS	O
NMA	O
JRP	O
RNP	O
.	O

Background	O

Plasmodium	B-OG
malariae	I-OG
is	O
a	O
slow	O
-	O
growing	O
parasite	O
with	O
a	O
wide	O
geographic	O
distribution	O
.	O

Although	O
generally	O
regarded	O
as	O
a	O
benign	O
cause	O
of	O
malaria	B-DS
,	O
it	O
has	O
been	O
associated	O
with	O
nephrotic	B-DS
syndrome	I-DS
,	O
particularly	O
in	O
young	O
children	O
,	O
and	O
can	O
persist	O
in	O
the	O
host	O
for	O
years	O
.	O

Morbidity	O
associated	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
has	O
received	O
relatively	O
little	O
attention	O
,	O
and	O
the	O
risk	O
of	O
P	B-OG
.	I-OG
malariae	I-OG
-	O
associated	O
nephrotic	B-DS
syndrome	I-DS
is	O
unknown	O
.	O

Methodology	O
/	O
Principal	O
Findings	O

We	O
used	O
data	O
from	O
a	O
very	O
large	O
hospital	O
-	O
based	O
surveillance	O
system	O
incorporating	O
information	O
on	O
clinical	O
diagnoses	O
,	O
blood	O
cell	O
parameters	O
and	O
treatment	O
to	O
describe	O
the	O
demographic	O
distribution	O
,	O
morbidity	O
and	O
mortality	O
associated	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
in	O
southern	O
Papua	O
,	O
Indonesia	O
.	O

Between	O
April	O
2004	O
and	O
December	O
2013	O
there	O
were	O
1	O
,	O
054	O
,	O
674	O
patient	O
presentations	O
to	O
Mitra	O
Masyarakat	O
Hospital	O
of	O
which	O
196	O
,	O
380	O
(	O
18	O
.	O
6	O
%)	O
were	O
associated	O
with	O
malaria	B-DS
and	O
5	O
,	O
097	O
were	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
(	O
constituting	O
2	O
.	O
6	O
%	O
of	O
all	O
malaria	B-DS
cases	O
).	O

The	O
proportion	O
of	O
malaria	B-DS
cases	O
attributable	O
to	O
P	B-OG
.	I-OG
malariae	I-OG
increased	O
with	O
age	O
from	O
0	O
.	O
9	O
%	O
for	O
patients	O
under	O
one	O
year	O
old	O
to	O
3	O
.	O
1	O
%	O
for	O
patients	O
older	O
than	O
15	O
years	O
.	O

Overall	O
,	O
8	O
.	O
5	O
%	O
of	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
required	O
admission	O
to	O
hospital	O
and	O
the	O
median	O
length	O
of	O
stay	O
for	O
these	O
patients	O
was	O
2	O
.	O
5	O
days	O
(	O
Interquartile	O
Range	O
:	O
2	O
.	O
0	O
–	O
4	O
.	O
0	O
days	O
).	O

Patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
had	O
a	O
lower	O
mean	O
hemoglobin	B-GP
concentration	O
(	O
9	O
.	O
0g	O
/	O
dL	O
)	O
than	O
patients	O
with	O
P	B-OG
.	I-OG
falciparum	I-OG
(	O
9	O
.	O
5g	O
/	O
dL	O
),	O
P	B-OG
.	I-OG
vivax	I-OG
(	O
9	O
.	O
6g	O
/	O
dL	O
)	O
and	O
mixed	O
species	O
infections	B-DS
(	O
9	O
.	O
3g	O
/	O
dL	O
).	O

There	O
were	O
four	O
cases	O
of	O
nephrotic	B-DS
syndrome	I-DS
recorded	O
in	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
,	O
three	O
of	O
which	O
were	O
in	O
children	O
younger	O
than	O
5	O
years	O
old	O
,	O
giving	O
a	O
risk	O
in	O
this	O
age	O
group	O
of	O
0	O
.	O
47	O
%	O
(	O
95	O
%	O
Confidence	O
Interval	O
;	O
0	O
.	O
10	O
%	O
to	O
1	O
.	O
4	O
%).	O

Overall	O
,	O
2	O
.	O
4	O
%	O
(	O
n	O
=	O
16	O
)	O
of	O
patients	O
hospitalized	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
subsequently	O
died	O
in	O
hospital	O
,	O
similar	O
to	O
the	O
proportions	O
for	O
the	O
other	O
endemic	O
Plasmodium	B-OG
species	O
(	O
range	O
:	O
0	O
%	O
for	O
P	B-OG
.	I-OG
ovale	I-OG
to	O
1	O
.	O
6	O
%	O
for	O
P	B-OG
.	I-OG
falciparum	I-OG
).	O

Conclusions	O
/	O
Significance	O

Plasmodium	B-OG
malariae	I-OG
infection	B-DS
is	O
relatively	O
uncommon	O
in	O
Papua	O
,	O
Indonesia	O
but	O
is	O
associated	O
with	O
significant	O
morbidity	O
from	O
anemia	B-DS
and	O
a	O
similar	O
risk	O
of	O
mortality	O
to	O
patients	O
hospitalized	O
with	O
P	B-OG
.	I-OG
falciparum	I-OG
and	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
.	O

In	O
our	O
large	O
hospital	O
database	O
,	O
one	O
in	O
200	O
children	O
under	O
the	O
age	O
of	O
5	O
years	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
were	O
recorded	O
as	O
having	O
nephrotic	B-DS
syndrome	I-DS
.	O

Author	O
Summary	O

Plasmodium	B-OG
malariae	I-OG
is	O
a	O
relatively	O
rare	O
,	O
but	O
widely	O
distributed	O
,	O
cause	O
of	O
malaria	B-DS
.	O

It	O
can	O
persist	O
in	O
the	O
human	B-OG
host	O
for	O
years	O
,	O
often	O
without	O
causing	O
significant	O
symptoms	O
.	O

As	O
a	O
result	O
,	O
P	B-OG
.	I-OG
malariae	I-OG
will	O
be	O
a	O
very	O
difficult	O
species	O
to	O
eradicate	O
.	O

Our	O
study	O
used	O
data	O
from	O
a	O
routine	O
hospital	O
-	O
based	O
surveillance	O
system	O
in	O
southern	O
Papua	O
,	O
Indonesia	O
to	O
describe	O
the	O
clinical	O
epidemiology	O
of	O
P	B-DS
.	I-DS
malariae	I-DS
infections	I-DS
.	O

Over	O
a	O
10	O
-	O
year	O
period	O
there	O
were	O
5	O
,	O
097	O
patient	O
presentations	O
to	O
Mitra	O
Masyarakat	O
Hospital	O
associated	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
constituting	O
2	O
.	O
6	O
%	O
of	O
all	O
malaria	B-DS
cases	O
.	O

Patients	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
malaria	B-DS
had	O
a	O
significantly	O
older	O
age	O
distribution	O
than	O
those	O
with	O
P	B-DS
.	I-DS
vivax	I-DS
infections	I-DS
.	O

They	O
also	O
had	O
lower	O
mean	O
hemoglobin	B-GP
concentrations	O
than	O
patients	O
infected	O
with	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
P	B-OG
.	I-OG
vivax	I-OG
or	O
mixed	O
Plasmodium	B-OG
species	O
.	O

We	O
speculate	O
that	O
this	O
may	O
be	O
due	O
to	O
chronic	B-DS
hemolysis	I-DS
of	O
parasitized	O
and	O
non	O
-	O
parasitized	O
red	O
cells	O
as	O
a	O
result	O
of	O
persistent	O
infection	B-DS
.	O

One	O
in	O
200	O
children	O
under	O
the	O
age	O
of	O
5	O
years	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
were	O
recorded	O
as	O
having	O
nephrotic	B-DS
syndrome	I-DS
,	O
a	O
well	O
-	O
known	O
but	O
to	O
date	O
unquantified	O
complication	O
.	O

Overall	O
,	O
0	O
.	O
3	O
%	O
of	O
patients	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
malaria	B-DS
died	O
.	O

These	O
findings	O
emphasize	O
the	O
need	O
to	O
consider	O
this	O
parasite	O
when	O
designing	O
comprehensive	O
malaria	B-DS
elimination	O
strategies	O
.	O

Introduction	O

Plasmodium	B-OG
malariae	I-OG
is	O
one	O
of	O
the	O
five	O
Plasmodium	B-OG
species	O
that	O
commonly	O
infect	O
humans	B-OG
.	O

The	O
global	O
incidence	O
of	O
infection	B-DS
by	O
this	O
species	O
is	O
unknown	O
but	O
is	O
thought	O
to	O
be	O
significantly	O
lower	O
than	O
for	O
P	B-OG
.	I-OG
falciparum	I-OG
[	O
1	O
].	O
Plasmodium	B-OG
malariae	I-OG
is	O
endemic	O
in	O
parts	O
of	O
Africa	O
[	O
2	O
–	O
4	O
],	O
South	O
America	O
[	O
5	O
,	O
6	O
],	O
Asia	O
[	O
7	O
–	O
10	O
]	O
and	O
the	O
Western	O
Pacific	O
[	O
11	O
].	O

Infection	B-DS
is	O
often	O
asymptomatic	O
[	O
12	O
]	O
and	O
severe	O
disease	O
is	O
thought	O
to	O
be	O
rare	O
.	O

However	O
,	O
untreated	O
infection	B-DS
has	O
been	O
reported	O
to	O
lead	O
to	O
nephrotic	B-DS
syndrome	I-DS
[	O
13	O
–	O
15	O
]	O
and	O
albuminuria	B-DS
was	O
commonly	O
noted	O
in	O
patients	O
treated	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
for	O
neurosyphilis	B-DS
in	O
the	O
1930s	O
[	O
16	O
].	O

Given	O
the	O
parasite	O
’	O
s	O
ability	O
to	O
survive	O
in	O
the	O
human	B-OG
host	O
at	O
low	O
parasitemias	B-DS
for	O
decades	O
[	O
17	O
],	O
chronic	O
morbidity	O
related	O
to	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
is	O
likely	O
to	O
occur	O
.	O

Global	O
malaria	B-DS
elimination	O
strategies	O
justifiably	O
target	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
which	O
is	O
associated	O
with	O
the	O
greatest	O
risk	O
of	O
acute	O
morbidity	O
and	O
mortality	O
.	O

When	O
such	O
malaria	B-DS
control	O
strategies	O
are	O
successful	O
,	O
the	O
fall	O
in	O
P	B-OG
.	I-OG
falciparum	I-OG
endemicity	O
is	O
often	O
associated	O
with	O
a	O
relative	O
rise	O
in	O
the	O
burden	O
of	O
malarial	O
disease	O
caused	O
by	O
the	O
non	O
-	O
falciparum	B-DS
malarias	I-DS
[	O
18	O
,	O
19	O
].	O

This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
demographic	O
distribution	O
,	O
morbidity	O
and	O
mortality	O
associated	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
in	O
southern	O
Papua	O
,	O
Indonesia	O
,	O
a	O
malarious	O
region	O
coendemic	O
for	O
four	O
Plasmodium	B-OG
species	O
–	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
P	B-OG
.	I-OG
vivax	I-OG
,	O
P	B-OG
.	I-OG
malariae	I-OG
and	O
P	B-OG
.	I-OG
ovale	I-OG
.	O

Understanding	O
the	O
features	O
of	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
will	O
be	O
important	O
for	O
guiding	O
clinical	O
management	O
and	O
eventual	O
eradication	O
of	O
this	O
species	O
.	O

Methods	O

Study	O
site	O

This	O
study	O
was	O
conducted	O
at	O
Rumah	O
Sakit	O
Mitra	O
Masyarakat	O
(	O
RSMM	O
),	O
the	O
major	O
referral	O
hospital	O
in	O
Timika	O
,	O
southcentral	O
Papua	O
,	O
Indonesia	O
.	O

The	O
characteristics	O
of	O
this	O
hospital	O
and	O
the	O
surrounding	O
region	O
have	O
been	O
described	O
in	O
detail	O
elsewhere	O
[	O
20	O
,	O
21	O
].	O

In	O
brief	O
,	O
Timika	O
,	O
has	O
a	O
population	O
of	O
approximately	O
200	O
,	O
000	O
people	O
and	O
is	O
situated	O
in	O
the	O
lowlands	O
,	O
about	O
50km	O
south	O
of	O
a	O
large	O
copper	O
and	O
gold	O
mine	O
.	O

It	O
has	O
a	O
tropical	O
climate	O
with	O
rainfall	O
occurring	O
year	O
-	O
round	O
with	O
minimal	O
seasonal	O
variation	O
.	O

Timika	O
has	O
a	O
diverse	O
ethnic	O
population	O
comprised	O
of	O
Highland	O
Papuans	O
,	O
Lowland	O
Papuans	O
(	O
both	O
of	O
Melanesian	O
descent	O
)	O
and	O
non	O
-	O
Papuans	O
(	O
mostly	O
of	O
Indonesian	O
descent	O
).	O

Rumah	O
Sakit	O
Mitra	O
Masyarakat	O
has	O
110	O
beds	O
,	O
a	O
24h	O
emergency	O
department	O
,	O
a	O
high	O
dependency	O
unit	O
with	O
facilities	O
for	O
intravenous	O
infusions	O
,	O
peritoneal	O
dialysis	O
and	O
monitoring	O
but	O
not	O
mechanical	O
ventilation	O
,	O
and	O
an	O
outpatient	O
department	O
that	O
sees	O
approximately	O
300	O
patients	O
per	O
day	O
,	O
6	O
days	O
per	O
week	O
.	O

Papua	O
has	O
the	O
highest	O
burden	O
of	O
malaria	B-DS
in	O
Indonesia	O
with	O
an	O
estimated	O
incidence	O
in	O
Timika	O
of	O
876	O
episodes	O
per	O
1	O
,	O
000	O
per	O
year	O
(	O
range	O
:	O
711	O
–	O
906	O
)	O
[	O
20	O
].	O

High	O
frequencies	O
of	O
drug	O
resistant	O
P	B-OG
.	I-OG
falciparum	I-OG
and	O
P	B-OG
.	I-OG
vivax	I-OG
strains	O
have	O
been	O
reported	O
[	O
22	O
]	O
although	O
P	B-OG
.	I-OG
malariae	I-OG
remains	O
sensitive	O
to	O
chloroquine	O
[	O
23	O
].	O

Malaria	B-DS
transmission	O
is	O
perennial	O
and	O
most	O
intense	O
in	O
the	O
lowland	O
regions	O
.	O

In	O
view	O
of	O
the	O
high	O
levels	O
of	O
antimalarial	O
drug	O
resistance	O
exhibited	O
by	O
both	O
P	B-OG
.	I-OG
falciparum	I-OG
and	O
P	B-OG
.	I-OG
vivax	I-OG
,	O
antimalarial	O
policy	O
for	O
uncomplicated	O
malaria	B-DS
due	O
to	O
any	O
Plasmodium	B-OG
species	O
was	O
changed	O
in	O
March	O
2006	O
from	O
oral	O
quinine	O
to	O
dihydroartemisinin	O
-	O
piperaquine	O
,	O
an	O
artemisinin	O
combination	O
therapy	O
(	O
ACT	O
).	O

In	O
order	O
to	O
monitor	O
the	O
impact	O
of	O
ACT	O
on	O
malaria	B-DS
morbidity	O
and	O
mortality	O
,	O
a	O
hospital	O
surveillance	O
system	O
was	O
established	O
in	O
2004	O
and	O
maintained	O
until	O
2013	O
.	O

Data	O
collection	O
procedures	O

Data	O
from	O
all	O
patient	O
presentations	O
to	O
RSMM	O
between	O
April	O
2004	O
and	O
December	O
2013	O
were	O
eligible	O
for	O
inclusion	O
in	O
this	O
study	O
.	O

Hospital	O
administrators	O
entered	O
demographic	O
and	O
diagnostic	O
data	O
into	O
an	O
electronic	O
database	O
(	O
Q	O
-	O
Pro	O
software	O
,	O
Jakarta	O
,	O
Indonesia	O
)	O
for	O
all	O
patients	O
presenting	O
to	O
the	O
hospital	O
,	O
regardless	O
of	O
department	O
.	O

Data	O
collected	O
included	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
pregnancy	O
status	O
and	O
diagnoses	O
classified	O
according	O
to	O
the	O
International	O
Classification	O
of	O
Diseases	O
,	O
version	O
10	O
.	O

The	O
latter	O
was	O
based	O
on	O
the	O
opinion	O
of	O
the	O
treating	O
physician	O
after	O
clinical	O
investigation	O
.	O

The	O
results	O
of	O
full	O
blood	O
counts	O
from	O
the	O
hospital	O
’	O
s	O
Coulter	O
Counter	O
were	O
entered	O
automatically	O
into	O
a	O
separate	O
database	O
and	O
prescription	O
data	O
from	O
the	O
hospital	O
pharmacy	O
were	O
entered	O
manually	O
into	O
a	O
further	O
database	O
by	O
the	O
pharmacist	O
filling	O
the	O
prescription	O
.	O

Records	O
from	O
all	O
three	O
databases	O
were	O
identified	O
using	O
the	O
patient	O
’	O
s	O
unique	O
hospital	O
identification	O
number	O
.	O

Previous	O
published	O
analyses	O
have	O
included	O
data	O
from	O
patients	O
presenting	O
to	O
RSMM	O
between	O
2004	O
and	O
the	O
end	O
of	O
2012	O
[	O
24	O
,	O
25	O
].	O

Hospital	O
guidelines	O
dictated	O
that	O
all	O
febrile	O
patients	O
seen	O
in	O
the	O
outpatients	O
department	O
and	O
all	O
inpatients	O
regardless	O
of	O
clinical	O
diagnosis	O
had	O
a	O
blood	O
film	O
for	O
malaria	B-DS
.	O

Giemsa	O
-	O
stained	O
thick	O
and	O
thin	O
films	O
were	O
considered	O
negative	O
after	O
microscopic	O
assessment	O
of	O
100	O
high	O
power	O
fields	O
.	O

Hospital	O
microscopists	O
underwent	O
regular	O
training	O
and	O
quality	O
assurance	O
procedures	O
to	O
ensure	O
a	O
high	O
standard	O
of	O
microscopy	O
[	O
21	O
].	O

Clinical	O
,	O
hematological	O
and	O
prescription	O
data	O
were	O
merged	O
sequentially	O
by	O
creating	O
all	O
possible	O
pairwise	O
combinations	O
for	O
a	O
given	O
unique	O
hospital	O
identification	O
number	O
.	O

Sets	O
where	O
the	O
date	O
of	O
the	O
laboratory	O
record	O
or	O
prescription	O
fell	O
between	O
the	O
date	O
of	O
admission	O
and	O
discharge	O
were	O
retained	O
.	O

In	O
cases	O
where	O
there	O
was	O
more	O
than	O
one	O
hemoglobin	B-GP
or	O
platelet	O
count	O
during	O
a	O
single	O
presentation	O
,	O
only	O
the	O
lowest	O
value	O
was	O
kept	O
.	O

Both	O
the	O
minimum	O
and	O
the	O
maximum	O
white	O
cell	O
count	O
were	O
kept	O
.	O

Severe	O
anemia	B-DS
was	O
defined	O
as	O
a	O
hemoglobin	B-GP
less	O
than	O
5g	O
/	O
dL	O
but	O
in	O
accordance	O
with	O
2014	O
World	O
Health	O
Organization	O
severe	O
malarial	O
anemia	B-DS
definitions	O
,	O
we	O
also	O
conducted	O
subanalyses	O
in	O
which	O
severe	O
anemia	B-DS
was	O
defined	O
as	O
a	O
hemoglobin	B-GP
<	O
5g	O
/	O
dL	O
in	O
children	O
under	O
12	O
years	O
of	O
age	O
and	O
<	O
7g	O
/	O
dL	O
in	O
adults	O
≥	O
12	O
years	O
of	O
age	O
[	O
26	O
].	O

Severe	O
thrombocytopenia	B-DS
was	O
defined	O
as	O
a	O
platelet	O
count	O
less	O
than	O
50x103	O
/	O
μL	O
.	O

White	O
cell	O
counts	O
were	O
categorized	O
as	O
normal	O
or	O
abnormal	O
according	O
to	O
age	O
-	O
specific	O
normal	O
ranges	O
[	O
27	O
].	O

Statistical	O
analysis	O

Analyses	O
were	O
performed	O
using	O
STATA	O
version	O
13	O
.	O
1	O
(	O
College	O
Station	O
,	O
Texas	O
,	O
USA	O
).	O

Anemia	B-DS
,	O
thrombocytopenia	B-DS
,	O
admission	O
to	O
hospital	O
and	O
length	O
of	O
stay	O
were	O
used	O
to	O
explore	O
the	O
morbidity	O
associated	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
and	O
were	O
compared	O
between	O
patients	O
infected	O
with	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
P	B-OG
.	I-OG
vivax	I-OG
,	O
P	B-OG
.	I-OG
ovale	I-OG
(	O
where	O
numbers	O
allowed	O
)	O
and	O
mixed	O
Plasmodium	B-OG
species	O
infections	B-DS
.	O

We	O
also	O
examined	O
the	O
frequency	O
of	O
abnormal	O
white	O
cell	O
counts	O
and	O
selected	O
comorbidities	O
to	O
help	O
establish	O
whether	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
was	O
likely	O
to	O
have	O
been	O
the	O
sole	O
reason	O
for	O
presentation	O
.	O

Univariable	O
and	O
multivariable	O
logistic	O
regression	O
models	O
(	O
the	O
latter	O
adjusting	O
for	O
age	O
group	O
(<	O
1	O
year	O
,	O
1	O
to	O
<	O
5	O
years	O
,	O
5	O
to	O
<	O
15	O
years	O
,	O
≥	O
15	O
years	O
),	O
sex	O
,	O
ethnicity	O
(	O
non	O
-	O
Papuan	O
,	O
Highland	O
Papuan	O
,	O
Lowland	O
Papuan	O
),	O
pregnancy	O
status	O
and	O
white	O
cell	O
count	O
(	O
normal	O
,	O
abnormal	O
)	O
were	O
used	O
to	O
compare	O
the	O
odds	O
for	O
severe	O
anemia	B-DS
and	O
severe	O
thrombocytopenia	B-DS
between	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
and	O
those	O
with	O
infection	B-DS
by	O
the	O
other	O
Plasmodium	B-OG
species	O
listed	O
above	O
.	O

As	O
individuals	O
in	O
the	O
hospital	O
database	O
could	O
appear	O
more	O
than	O
once	O
,	O
robust	O
standard	O
errors	O
(	O
Huber	O
-	O
White	O
sandwich	O
estimator	O
)	O
were	O
calculated	O
,	O
accounting	O
for	O
within	O
-	O
patient	O
correlation	O
.	O

Given	O
the	O
very	O
large	O
numbers	O
of	O
patients	O
in	O
the	O
database	O
,	O
formal	O
tests	O
of	O
statistical	O
significance	O
were	O
only	O
done	O
in	O
the	O
context	O
of	O
univariable	O
and	O
multivariable	O
logistic	O
regression	O
models	O
.	O

Ethical	O
clearance	O

This	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
committees	O
of	O
the	O
University	O
of	O
Gajah	O
Mada	O
(	O
Yogyakarta	O
,	O
Indonesia	O
)	O
and	O
Menzies	O
School	O
of	O
Health	O
Research	O
(	O
Darwin	O
,	O
Australia	O
).	O

All	O
data	O
were	O
anonymized	O
.	O

Results	O

Between	O
April	O
2004	O
and	O
December	O
2013	O
there	O
were	O
1	O
,	O
054	O
,	O
674	O
presentations	O
to	O
RSMM	O
of	O
which	O
196	O
,	O
380	O
(	O
18	O
.	O
6	O
%)	O
were	O
associated	O
with	O
malaria	B-DS
.	O
Plasmodium	B-OG
malariae	I-OG
monoinfection	O
accounted	O
for	O
2	O
.	O
6	O
%	O
of	O
all	O
malaria	B-DS
cases	O
(	O
5	O
,	O
097	O
presentations	O
made	O
by	O
4	O
,	O
456	O
individuals	O
)	O
(	O
Table	O
1	O
).	O

Other	O
Plasmodium	B-OG
species	O
present	O
included	O
P	B-OG
.	I-OG
falciparum	I-OG
(	O
100	O
,	O
078	O
presentations	O
,	O
51	O
.	O
0	O
%),	O
P	B-OG
.	I-OG
vivax	I-OG
(	O
65	O
,	O
306	O
presentations	O
,	O
33	O
.	O
3	O
%),	O
P	B-OG
.	I-OG
ovale	I-OG
(	O
120	O
presentations	O
,	O
0	O
.	O
1	O
%)	O
and	O
mixed	O
Plasmodium	B-OG
species	O
(	O
25	O
,	O
779	O
presentations	O
,	O
13	O
.	O
1	O
%).	O

Two	O
hundred	O
and	O
forty	O
one	O
(	O
0	O
.	O
9	O
%)	O
of	O
the	O
mixed	O
species	O
infections	B-DS
included	O
P	B-OG
.	I-OG
malariae	I-OG
,	O
of	O
which	O
148	O
(	O
0	O
.	O
6	O
%)	O
were	O
in	O
combination	O
with	O
P	B-OG
.	I-OG
falciparum	I-OG
and	O
93	O
(	O
0	O
.	O
4	O
%)	O
were	O
with	O
P	B-OG
.	I-OG
vivax	I-OG
.	O

Overall	O
,	O
4	O
.	O
4	O
%	O
(	O
225	O
/	O
5	O
,	O
097	O
)	O
of	O
presentations	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
monoinfection	O
were	O
followed	O
by	O
a	O
further	O
presentation	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
within	O
one	O
year	O
.	O

The	O
median	O
day	O
of	O
representation	O
was	O
171	O
(	O
Interquartile	O
Range	O
[	O
IQR	O
]	O
86	O
–	O
266	O
)	O
with	O
no	O
significant	O
difference	O
in	O
the	O
crude	O
risk	O
between	O
those	O
treated	O
with	O
oral	O
quinine	O
and	O
those	O
treated	O
with	O
dihydroartemisinin	O
-	O
piperaquine	O
(	O
5	O
.	O
9	O
%	O
versus	O
4	O
.	O
4	O
%).	O

Only	O
1	O
.	O
3	O
%	O
(	O
10	O
,	O
886	O
/	O
858	O
,	O
294	O
)	O
of	O
patients	O
without	O
malaria	B-DS
,	O
1	O
.	O
9	O
%	O
(	O
1	O
,	O
892	O
/	O
100	O
,	O
078	O
)	O
of	O
patients	O
with	O
falciparum	B-DS
malaria	I-DS
and	O
1	O
.	O
3	O
%	O
(	O
868	O
/	O
65	O
,	O
306	O
)	O
of	O
patients	O
with	O
vivax	B-DS
malaria	I-DS
represented	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
within	O
a	O
year	O
.	O

Demographic	O
distribution	O
of	O
all	O
1	O
,	O
054	O
,	O
674	O
patient	O
presentations	O
.	O

Species	O

Negative	O

P	B-OG
.	I-OG
falciparum	I-OG

P	B-OG
.	I-OG
vivax	I-OG

P	B-OG
.	I-OG
ovale	I-OG

P	B-OG
.	I-OG
malariae	I-OG

Mixed	O
species	O

Total	O

n	O
(%)	O

n	O
(%)	O

n	O
(%)	O

n	O
(%)	O

n	O
(%)	O

n	O
(%)	O

n	O
(%)	O

Age	O
group	O

0	O
to	O
<	O
1	O

71	O
,	O
789	O
(	O
8	O
.	O
4	O
)	O

2	O
,	O
321	O
(	O
2	O
.	O
3	O
)	O

5	O
,	O
274	O
(	O
8	O
.	O
1	O
)	O

2	O
(	O
1	O
.	O
7	O
)	O

80	O
(	O
1	O
.	O
6	O
)	O

992	O
(	O
3	O
.	O
8	O
)	O

80	O
,	O
458	O
(	O
7	O
.	O
6	O
)	O

1	O
to	O
<	O
5	O

116	O
,	O
487	O
(	O
13	O
.	O
6	O
)	O

16	O
,	O
132	O
(	O
16	O
.	O
1	O
)	O

19	O
,	O
859	O
(	O
30	O
.	O
4	O
)	O

11	O
(	O
9	O
.	O
2	O
)	O

554	O
(	O
10	O
.	O
9	O
)	O

6	O
,	O
152	O
(	O
23	O
.	O
9	O
)	O

159	O
,	O
195	O
(	O
15	O
.	O
1	O
)	O

5	O
to	O
<	O
15	O

86	O
,	O
366	O
(	O
10	O
.	O
1	O
)	O

19	O
,	O
913	O
(	O
19	O
.	O
9	O
)	O

11	O
,	O
340	O
(	O
17	O
.	O
4	O
)	O

22	O
(	O
18	O
.	O
3	O
)	O

1	O
,	O
096	O
(	O
21	O
.	O
5	O
)	O

5	O
,	O
559	O
(	O
21	O
.	O
6	O
)	O

124	O
,	O
296	O
(	O
11	O
.	O
8	O
)	O

≥	O
15	O

583	O
,	O
607	O
(	O
68	O
.	O
0	O
)	O

61	O
,	O
707	O
(	O
61	O
.	O
7	O
)	O

28	O
,	O
832	O
(	O
44	O
.	O
1	O
)	O

85	O
(	O
70	O
.	O
8	O
)	O

3	O
,	O
367	O
(	O
66	O
.	O
1	O
)	O

13	O
,	O
075	O
(	O
50	O
.	O
7	O
)	O

690	O
,	O
673	O
(	O
65	O
.	O
5	O
)	O

Sex	O

Male	O

378	O
,	O
074	O
(	O
44	O
.	O
0	O
)	O

49	O
,	O
592	O
(	O
49	O
.	O
6	O
)	O

32	O
,	O
970	O
(	O
50	O
.	O
5	O
)	O

68	O
(	O
56	O
.	O
7	O
)	O

2	O
,	O
575	O
(	O
50	O
.	O
5	O
)	O

13	O
,	O
068	O
(	O
50	O
.	O
7	O
)	O

476	O
,	O
347	O
(	O
45	O
.	O
2	O
)	O

Female	O

480	O
,	O
220	O
(	O
56	O
.	O
0	O
)	O

50	O
,	O
486	O
(	O
50	O
.	O
4	O
)	O

32	O
,	O
336	O
(	O
49	O
.	O
5	O
)	O

52	O
(	O
43	O
.	O
3	O
)	O

2	O
,	O
522	O
(	O
49	O
.	O
5	O
)	O

12	O
,	O
711	O
(	O
49	O
.	O
3	O
)	O

578	O
,	O
327	O
(	O
54	O
.	O
8	O
)	O

Pregnant	O

No	O

399	O
,	O
336	O
(	O
83	O
.	O
2	O
)	O

47	O
,	O
808	O
(	O
94	O
.	O
7	O
)	O

31	O
,	O
215	O
(	O
96	O
.	O
5	O
)	O

49	O
(	O
94	O
.	O
2	O
)	O

2	O
,	O
395	O
(	O
95	O
.	O
0	O
)	O

12	O
,	O
264	O
(	O
96	O
.	O
5	O
)	O

493	O
,	O
067	O
(	O
85	O
.	O
3	O
)	O

Yes	O

80	O
,	O
884	O
(	O
16	O
.	O
8	O
)	O

2	O
,	O
678	O
(	O
5	O
.	O
3	O
)	O

1	O
,	O
121	O
(	O
3	O
.	O
5	O
)	O

3	O
(	O
5	O
.	O
8	O
)	O

127	O
(	O
5	O
.	O
0	O
)	O

447	O
(	O
3	O
.	O
5	O
)	O

85	O
,	O
260	O
(	O
14	O
.	O
7	O
)	O

Ethnic	O
group	O

Non	O
-	O
Papuan	O

152	O
,	O
502	O
(	O
17	O
.	O
8	O
)	O

8	O
,	O
305	O
(	O
8	O
.	O
3	O
)	O

7	O
,	O
539	O
(	O
11	O
.	O
6	O
)	O

9	O
(	O
7	O
.	O
5	O
)	O

164	O
(	O
3	O
.	O
2	O
)	O

1	O
,	O
324	O
(	O
5	O
.	O
1	O
)	O

169	O
,	O
843	O
(	O
16	O
.	O
1	O
)	O

Highland	O
Papuan	O

576	O
,	O
524	O
(	O
67	O
.	O
3	O
)	O

81	O
,	O
706	O
(	O
81	O
.	O
7	O
)	O

52	O
,	O
905	O
(	O
81	O
.	O
1	O
)	O

106	O
(	O
88	O
.	O
3	O
)	O

4	O
,	O
452	O
(	O
87	O
.	O
3	O
)	O

22	O
,	O
434	O
(	O
87	O
.	O
0	O
)	O

738	O
,	O
127	O
(	O
70	O
.	O
1	O
)	O

Lowland	O
Papuan	O

128	O
,	O
027	O
(	O
14	O
.	O
9	O
)	O

9	O
,	O
982	O
(	O
10	O
)	O

4	O
,	O
820	O
(	O
7	O
.	O
4	O
)	O

5	O
(	O
4	O
.	O
2	O
)	O

481	O
(	O
9	O
.	O
4	O
)	O

2	O
,	O
015	O
(	O
7	O
.	O
8	O
)	O

145	O
,	O
330	O
(	O
13	O
.	O
8	O
)	O

Total	O

858	O
,	O
294	O
(	O
100	O
)	O

100	O
,	O
078	O
(	O
100	O
)	O

65	O
,	O
306	O
(	O
100	O
)	O

120	O
(	O
100	O
)	O

5	O
,	O
097	O
(	O
100	O
)	O

25	O
,	O
779	O
(	O
100	O
)	O

1	O
,	O
054	O
,	O
674	O
(	O
100	O
)	O

Abbreviations	O
:	O
n	O
,	O
number	O

Age	O
data	O
were	O
missing	O
in	O
52	O
cases	O
,	O
and	O
ethnicity	O
data	O
were	O
missing	O
in	O
1	O
,	O
374	O
cases	O

The	O
age	O
distribution	O
of	O
all	O
patients	O
presenting	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
monoinfection	O
was	O
similar	O
to	O
P	B-OG
.	I-OG
falciparum	I-OG
(	O
median	O
21	O
.	O
7	O
and	O
20	O
.	O
1	O
years	O
respectively	O
),	O
but	O
substantially	O
older	O
than	O
for	O
P	B-OG
.	I-OG
vivax	I-OG
(	O
median	O
10	O
.	O
0	O
years	O
)	O
and	O
mixed	B-DS
infections	I-DS
(	O
15	O
.	O
1	O
years	O
).	O

For	O
all	O
species	O
,	O
there	O
was	O
a	O
bimodal	O
distribution	O
of	O
age	O
at	O
presentation	O
with	O
a	O
peak	O
in	O
children	O
under	O
5	O
years	O
of	O
age	O
and	O
another	O
in	O
early	O
adulthood	O
.	O

The	O
childhood	O
peak	O
for	O
P	B-OG
.	I-OG
malariae	I-OG
was	O
less	O
pronounced	O
than	O
for	O
the	O
other	O
species	O
(	O
P	B-OG
.	I-OG
ovale	I-OG
excepted	O
)	O
(	O
see	O
Fig	O
1	O
).	O

The	O
proportion	O
of	O
malaria	B-DS
presentations	O
attributable	O
to	O
P	B-OG
.	I-OG
malariae	I-OG
increased	O
from	O
0	O
.	O
9	O
%	O
(	O
80	O
/	O
8	O
,	O
669	O
)	O
for	O
patients	O
less	O
than	O
one	O
year	O
of	O
age	O
to	O
3	O
.	O
1	O
%	O
(	O
3	O
,	O
367	O
/	O
107	O
,	O
066	O
)	O
for	O
patients	O
older	O
than	O
15	O
years	O
(	O
Fig	O
2	O
).	O

Age	O
distributions	O
of	O
patients	O
presenting	O
to	O
RSMM	O
by	O
Plasmodium	B-OG
species	O
.	O

Vertical	O
lines	O
represent	O
median	O
age	O
.	O

Percent	O
of	O
malaria	B-DS
cases	O
due	O
to	O
Plasmodium	B-OG
malariae	I-OG
by	O
age	O
,	O
with	O
polynomial	O
fit	O
line	O
.	O

Age	O
truncated	O
at	O
70	O
years	O
to	O
maintain	O
stability	O
of	O
fit	O
line	O
.	O

The	O
majority	O
of	O
presentations	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
were	O
in	O
Highland	O
Papuans	O
(	O
4	O
,	O
452	O
,	O
87	O
.	O
3	O
%),	O
but	O
this	O
predominance	O
was	O
also	O
apparent	O
for	O
the	O
other	O
Plasmodium	B-OG
species	O
(	O
range	O
81	O
.	O
0	O
–	O
88	O
.	O
3	O
%)	O
and	O
patients	O
without	O
malaria	B-DS
(	O
67	O
.	O
2	O
%).	O

Hospitalization	O
,	O
treatment	O
and	O
comorbidity	O

In	O
total	O
,	O
8	O
.	O
5	O
%	O
(	O
432	O
/	O
5	O
,	O
097	O
)	O
of	O
the	O
patients	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
monoinfection	O
required	O
admission	O
to	O
hospital	O
,	O
less	O
than	O
the	O
proportion	O
for	O
patients	O
with	O
P	B-OG
.	I-OG
falciparum	I-OG
(	O
17	O
.	O
4	O
%)	O
and	O
mixed	B-DS
infections	I-DS
(	O
15	O
.	O
3	O
%),	O
but	O
similar	O
to	O
those	O
with	O
P	B-OG
.	I-OG
vivax	I-OG
(	O
9	O
.	O
4	O
%)	O
and	O
P	B-OG
.	I-OG
ovale	I-OG
(	O
8	O
.	O
3	O
%)	O
infections	B-DS
.	O

The	O
median	O
length	O
of	O
stay	O
for	O
those	O
admitted	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
was	O
2	O
.	O
5	O
days	O
(	O
IQR	O
2	O
.	O
0	O
–	O
4	O
.	O
0	O
days	O
);	O
shorter	O
than	O
for	O
those	O
without	O
malaria	B-DS
3	O
.	O
0	O
days	O
(	O
IQR	O
2	O
.	O
0	O
–	O
5	O
.	O
0	O
days	O
)	O
but	O
longer	O
than	O
for	O
patients	O
with	O
other	O
Plasmodium	B-OG
species	O
infections	B-DS
(	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
2	O
.	O
0	O
days	O
(	O
2	O
.	O
0	O
–	O
4	O
.	O
0	O
),	O
P	B-OG
.	I-OG
vivax	I-OG
,	O
2	O
.	O
0	O
days	O
(	O
2	O
.	O
0	O
–	O
4	O
.	O
0	O
),	O
P	B-OG
.	I-OG
ovale	I-OG
,	O
2	O
.	O
0	O
days	O
(	O
1	O
.	O
0	O
–	O
3	O
.	O
0	O
)	O
and	O
mixed	O
species	O
,	O
2	O
.	O
0	O
days	O
(	O
2	O
.	O
0	O
–	O
4	O
.	O
0	O
).	O

Admission	O
for	O
greater	O
than	O
5	O
days	O
was	O
required	O
for	O
17	O
.	O
4	O
%	O
(	O
75	O
/	O
432	O
)	O
of	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
,	O
19	O
.	O
4	O
%	O
(	O
13	O
,	O
130	O
/	O
67	O
,	O
365	O
)	O
of	O
those	O
without	O
malaria	B-DS
,	O
11	O
.	O
2	O
%	O
(	O
1	O
,	O
942	O
/	O
17	O
,	O
387	O
)	O
with	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
13	O
.	O
0	O
%	O
(	O
795	O
/	O
6	O
,	O
116	O
)	O
with	O
P	B-OG
.	I-OG
vivax	I-OG
,	O
10	O
.	O
0	O
%	O
(	O
1	O
/	O
10	O
)	O
with	O
P	B-OG
.	I-OG
ovale	I-OG
and	O
12	O
.	O
0	O
%	O
(	O
473	O
/	O
3	O
,	O
945	O
)	O
with	O
mixed	O
species	O
infections	B-DS
.	O

Assuming	O
100	O
%	O
bed	O
occupancy	O
over	O
the	O
study	O
period	O
,	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
accounted	O
for	O
0	O
.	O
4	O
%	O
(	O
1	O
,	O
733	O
/	O
391	O
,	O
710	O
)	O
of	O
total	O
hospital	O
bed	O
occupancy	O
.	O

The	O
corresponding	O
figures	O
for	O
the	O
other	O
Plasmodium	B-OG
species	O
were	O
14	O
.	O
6	O
%	O
(	O
57	O
,	O
037	O
bed	O
days	O
)	O
for	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
5	O
.	O
4	O
%	O
(	O
21	O
,	O
298	O
bed	O
days	O
)	O
for	O
P	B-OG
.	I-OG
vivax	I-OG
,	O
0	O
.	O
006	O
%	O
(	O
24	O
bed	O
days	O
)	O
for	O
P	B-OG
.	I-OG
ovale	I-OG
and	O
3	O
.	O
4	O
%	O
(	O
13	O
,	O
241	O
bed	O
days	O
)	O
for	O
mixed	O
species	O
infections	B-DS
.	O

Overall	O
,	O
4	O
,	O
691	O
(	O
92	O
.	O
0	O
%)	O
patient	O
presentations	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
were	O
matched	O
with	O
corresponding	O
pharmacy	O
data	O
.	O

In	O
4	O
,	O
459	O
of	O
these	O
cases	O
(	O
95	O
.	O
1	O
%),	O
treatment	O
was	O
with	O
oral	O
therapy	O
alone	O
.	O

Prior	O
to	O
March	O
2006	O
(	O
401	O
cases	O
),	O
the	O
majority	O
of	O
patients	O
received	O
either	O
oral	O
quinine	O
(	O
n	O
=	O
212	O
;	O
52	O
.	O
9	O
%),	O
chloroquine	O
(	O
n	O
=	O
76	O
;	O
19	O
.	O
0	O
%)	O
or	O
doxycycline	O
(	O
n	O
=	O
71	O
,	O
17	O
.	O
7	O
%)	O
with	O
small	O
numbers	O
receiving	O
sulphadoxine	O
-	O
pyrimethamine	O
(	O
n	O
=	O
21	O
,	O
5	O
.	O
2	O
%).	O

After	O
the	O
change	O
of	O
malaria	B-DS
treatment	O
protocols	O
to	O
ACT	O
in	O
March	O
2006	O
(	O
4	O
,	O
290	O
cases	O
),	O
4	O
,	O
157	O
(	O
96	O
.	O
9	O
%)	O
were	O
treated	O
with	O
ACT	O
(	O
3	O
,	O
898	O
(	O
90	O
.	O
9	O
%)	O
with	O
dihydroartemisinin	O
-	O
piperaquine	O
and	O
261	O
(	O
6	O
.	O
1	O
%)	O
with	O
artesunate	O
-	O
amodiaquine	O
(	O
two	O
patients	O
received	O
both	O
combinations	O
)).	O

In	O
232	O
cases	O
(	O
4	O
.	O
9	O
%),	O
patients	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
were	O
treated	O
with	O
parenteral	O
therapy	O
;	O
intravenous	O
quinine	O
prior	O
to	O
April	O
2006	O
(	O
23	O
cases	O
,	O
9	O
.	O
9	O
%)	O
and	O
intravenous	O
artesunate	O
after	O
this	O
date	O
(	O
209	O
cases	O
,	O
90	O
.	O
1	O
%).	O

Of	O
the	O
5	O
,	O
097	O
presentations	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
monoinfection	O
,	O
1	O
,	O
516	O
(	O
29	O
.	O
7	O
%)	O
were	O
associated	O
with	O
at	O
least	O
one	O
additional	O
clinical	O
diagnosis	O
and	O
this	O
figure	O
rose	O
to	O
96	O
.	O
5	O
%	O
(	O
417	O
presentations	O
)	O
in	O
those	O
admitted	O
to	O
hospital	O
.	O

The	O
overall	O
proportions	O
with	O
comorbidity	O
for	O
those	O
with	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
P	B-OG
.	I-OG
vivax	I-OG
and	O
mixed	B-DS
infections	I-DS
were	O
slightly	O
higher	O
:	O
32	O
.	O
7	O
%,	O
30	O
.	O
5	O
%	O
and	O
31	O
.	O
0	O
%	O
respectively	O
.	O

Thirty	O
(	O
0	O
.	O
6	O
%)	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
presented	O
following	O
trauma	O
and	O
therefore	O
presumably	O
had	O
incidental	O
parasitemias	B-DS
(	O
Table	O
2	O
).	O

Overall	O
,	O
16	O
(	O
0	O
.	O
3	O
%)	O
of	O
the	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
had	O
documented	O
renal	B-DS
disease	I-DS
,	O
of	O
whom	O
4	O
(	O
0	O
.	O
1	O
%)	O
were	O
recorded	O
as	O
having	O
nephrotic	B-DS
syndrome	I-DS
.	O

Although	O
numbers	O
were	O
small	O
,	O
this	O
proportion	O
was	O
approximately	O
10	O
-	O
fold	O
higher	O
than	O
for	O
the	O
other	O
Plasmodium	B-OG
species	O
(	O
Table	O
2	O
).	O

All	O
four	O
of	O
the	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
and	O
nephrotic	B-DS
syndrome	I-DS
were	O
under	O
the	O
age	O
of	O
15	O
years	O
and	O
three	O
were	O
under	O
the	O
age	O
of	O
5	O
years	O
giving	O
a	O
risk	O
of	O
nephrotic	B-DS
syndrome	I-DS
of	O
0	O
.	O
23	O
%	O
(	O
95	O
%	O
Confidence	O
Interval	O
[	O
95	O
%	O
CI	O
];	O
0	O
.	O
06	O
%	O
to	O
0	O
.	O
59	O
%)	O
in	O
children	O
under	O
15	O
years	O
and	O
0	O
.	O
47	O
%	O
(	O
95	O
%	O
CI	O
;	O
0	O
.	O
10	O
%	O
to	O
1	O
.	O
4	O
%)	O
in	O
children	O
aged	O
under	O
5	O
years	O
old	O
.	O

None	O
of	O
the	O
4	O
patients	O
with	O
nephrotic	B-DS
syndrome	I-DS
died	O
at	O
the	O
hospital	O
prior	O
to	O
the	O
end	O
of	O
the	O
study	O
.	O

Comorbidities	O
in	O
patients	O
presenting	O
to	O
Rumah	O
Sakit	O
Mitra	O
Masyarakat	O
by	O
Plasmodium	B-OG
species	O
.	O

Species	O

Negative	O

P	B-OG
.	I-OG
falciparum	I-OG

P	B-OG
.	I-OG
vivax	I-OG

P	B-OG
.	I-OG
ovale	I-OG

P	B-OG
.	I-OG
malariae	I-OG

Mixed	O
species	O

Total	O

n	O
(%)	O

n	O
(%)	O

n	O
(%)	O

n	O
(%)	O

n	O
(%)	O

n	O
(%)	O

n	O
(%)	O

Pneumonia	B-DS

No	O

834	O
,	O
991	O
(	O
97	O
.	O
3	O
)	O

98	O
,	O
983	O
(	O
98	O
.	O
9	O
)	O

64	O
,	O
368	O
(	O
98	O
.	O
6	O
)	O

119	O
(	O
99	O
.	O
2	O
)	O

5	O
,	O
053	O
(	O
99	O
.	O
1	O
)	O

25	O
,	O
436	O
(	O
98	O
.	O
7	O
)	O

1	O
,	O
028	O
,	O
950	O
(	O
97	O
.	O
6	O
)	O

Yes	O

23	O
,	O
303	O
(	O
2	O
.	O
7	O
)	O

1	O
,	O
095	O
(	O
1	O
.	O
1	O
)	O

938	O
(	O
1	O
.	O
4	O
)	O

1	O
(	O
0	O
.	O
8	O
)	O

44	O
(	O
0	O
.	O
9	O
)	O

343	O
(	O
1	O
.	O
3	O
)	O

25	O
,	O
724	O
(	O
2	O
.	O
4	O
)	O

Renal	B-DS
Disease	I-DS

No	O

855	O
,	O
722	O
(	O
99	O
.	O
7	O
)	O

99	O
,	O
663	O
(	O
99	O
.	O
6	O
)	O

65	O
,	O
225	O
(	O
99	O
.	O
9	O
)	O

120	O
(	O
100	O
)	O

5	O
,	O
081	O
(	O
99	O
.	O
7	O
)	O

25	O
,	O
695	O
(	O
99	O
.	O
7	O
)	O

1	O
,	O
051	O
,	O
506	O
(	O
99	O
.	O
7	O
)	O

Yes	O

2	O
,	O
572	O
(	O
0	O
.	O
3	O
)	O

415	O
(	O
0	O
.	O
4	O
)	O

81	O
(	O
0	O
.	O
1	O
)	O

0	O
(	O
0	O
)	O

16	O
(	O
0	O
.	O
3	O
)	O

84	O
(	O
0	O
.	O
3	O
)	O

3	O
,	O
168	O
(	O
0	O
.	O
3	O
)	O

Nephrotic	B-DS
syndrome	I-DS

No	O

858	O
,	O
117	O
(	O
99	O
.	O
98	O
)	O

100	O
,	O
072	O
(	O
99	O
.	O
99	O
)	O

65	O
,	O
302	O
(	O
99	O
.	O
99	O
)	O

120	O
(	O
100	O
)	O

5	O
,	O
093	O
(	O
99	O
.	O
9	O
)	O

25	O
,	O
776	O
(	O
99	O
.	O
99	O
)	O

1	O
,	O
054	O
,	O
480	O
(	O
99	O
.	O
98	O
)	O

Yes	O

177	O
(	O
0	O
.	O
02	O
)	O

6	O
(	O
0	O
.	O
01	O
)	O

4	O
(	O
0	O
.	O
01	O
)	O

0	O
(	O
0	O
)	O

4	O
(	O
0	O
.	O
1	O
)	O

3	O
(	O
0	O
.	O
01	O
)	O

194	O
(	O
0	O
.	O
02	O
)	O

HIV	B-OG

No	O

840	O
,	O
095	O
(	O
97	O
.	O
9	O
)	O

99	O
,	O
498	O
(	O
99	O
.	O
4	O
)	O

65	O
,	O
029	O
(	O
99	O
.	O
6	O
)	O

119	O
(	O
99	O
.	O
2	O
)	O

5	O
,	O
072	O
(	O
99	O
.	O
5	O
)	O

25	O
,	O
661	O
(	O
99	O
.	O
5	O
)	O

1	O
,	O
035	O
,	O
474	O
(	O
98	O
.	O
2	O
)	O

Yes	O

18	O
,	O
199	O
(	O
2	O
.	O
1	O
)	O

580	O
(	O
0	O
.	O
6	O
)	O

277	O
(	O
0	O
.	O
4	O
)	O

1	O
(	O
0	O
.	O
8	O
)	O

25	O
(	O
0	O
.	O
5	O
)	O

118	O
(	O
0	O
.	O
5	O
)	O

19	O
,	O
200	O
(	O
1	O
.	O
8	O
)	O

Trauma	O

No	O

800	O
,	O
208	O
(	O
93	O
.	O
2	O
)	O

99	O
,	O
664	O
(	O
99	O
.	O
6	O
)	O

65	O
,	O
046	O
(	O
99	O
.	O
6	O
)	O

120	O
(	O
100	O
)	O

5	O
,	O
067	O
(	O
99	O
.	O
4	O
)	O

25	O
,	O
708	O
(	O
99	O
.	O
7	O
)	O

995	O
,	O
813	O
(	O
94	O
.	O
4	O
)	O

Yes	O

58	O
,	O
086	O
(	O
6	O
.	O
8	O
)	O

414	O
(	O
0	O
.	O
4	O
)	O

260	O
(	O
0	O
.	O
4	O
)	O

0	O
(	O
0	O
)	O

30	O
(	O
0	O
.	O
6	O
)	O

71	O
(	O
0	O
.	O
3	O
)	O

58	O
,	O
861	O
(	O
5	O
.	O
6	O
)	O

Abbreviations	O
:	O
n	O
;	O
number	O
,	O
HIV	B-OG
;	O
human	B-OG
immunodeficiency	I-OG
virus	I-OG

Hematological	O
morbidity	O

Hemoglobin	B-GP
concentrations	O
,	O
platelet	O
counts	O
and	O
white	O
cell	O
counts	O
were	O
available	O
in	O
22	O
.	O
9	O
%	O
(	O
241	O
,	O
594	O
),	O
22	O
.	O
4	O
%	O
(	O
236	O
,	O
536	O
)	O
and	O
22	O
.	O
7	O
%	O
(	O
239	O
,	O
444	O
)	O
of	O
all	O
patient	O
presentations	O
with	O
the	O
corresponding	O
figures	O
for	O
P	B-OG
.	I-OG
malariae	I-OG
cases	O
being	O
34	O
.	O
3	O
%	O
(	O
1	O
,	O
750	O
),	O
33	O
.	O
6	O
%	O
(	O
1	O
,	O
713	O
)	O
and	O
34	O
.	O
1	O
%	O
(	O
1	O
,	O
739	O
)	O
respectively	O
.	O

The	O
mean	O
hemoglobin	B-GP
concentration	O
was	O
9	O
.	O
0	O
g	O
/	O
dL	O
in	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
,	O
the	O
lowest	O
of	O
all	O
the	O
Plasmodium	B-OG
species	O
(	O
10	O
.	O
6g	O
/	O
dL	O
for	O
those	O
without	O
malaria	B-DS
,	O
9	O
.	O
5g	O
/	O
dL	O
for	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
9	O
.	O
6g	O
/	O
dL	O
for	O
P	B-OG
.	I-OG
vivax	I-OG
,	O
and	O
9	O
.	O
3g	O
/	O
dL	O
for	O
mixed	O
species	O
infections	B-DS
).	O

Overall	O
,	O
5	O
.	O
7	O
%	O
(	O
n	O
=	O
100	O
)	O
of	O
patients	O
presenting	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infections	I-DS
had	O
a	O
hemoglobin	B-GP
<	O
5g	O
/	O
dL	O
(	O
32	O
/	O
577	O
[	O
5	O
.	O
5	O
%]	O
of	O
those	O
<	O
12	O
years	O
and	O
68	O
/	O
1	O
,	O
173	O
[	O
5	O
.	O
8	O
%]	O
of	O
those	O
≥	O
12	O
years	O
).	O

This	O
was	O
similar	O
to	O
the	O
crude	O
proportions	O
for	O
P	B-OG
.	I-OG
falciparum	I-OG
and	O
P	B-OG
.	I-OG
vivax	I-OG
(	O
Table	O
3	O
).	O

Three	O
hundred	O
and	O
sixty	O
nine	O
(	O
21	O
.	O
1	O
%)	O
patients	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
malaria	B-DS
had	O
hemoglobin	B-GP
concentrations	O
under	O
7g	O
/	O
dL	O
(	O
151	O
/	O
577	O
[	O
26	O
.	O
2	O
%]	O
of	O
those	O
<	O
12	O
years	O
and	O
218	O
/	O
1	O
,	O
173	O
(	O
18	O
.	O
6	O
%)	O
of	O
those	O
≥	O
12	O
years	O
)	O
and	O
1	O
,	O
128	O
(	O
64	O
.	O
5	O
%)	O
had	O
a	O
hemoglobin	B-GP
under	O
10g	O
/	O
dL	O
.	O

After	O
controlling	O
for	O
confounding	O
factors	O
,	O
those	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
were	O
at	O
significantly	O
greater	O
risk	O
of	O
severe	O
anemia	B-DS
compared	O
to	O
those	O
without	O
Plasmodium	B-OG
infection	B-DS
both	O
when	O
defined	O
as	O
a	O
hemoglobin	B-GP
of	O
less	O
than	O
5g	O
/	O
dL	O
(	O
Adjusted	O
Odds	O
Ratio	O
[	O
AOR	O
];	O
2	O
.	O
29	O
,	O
95	O
%	O
CI	O
;	O
1	O
.	O
85	O
–	O
2	O
.	O
84	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
Table	O
4	O
)	O
and	O
as	O
per	O
2014	O
WHO	O
criteria	O
(	O
AOR	O
;	O
2	O
.	O
02	O
,	O
95	O
%	O
CI	O
;	O
1	O
.	O
75	O
–	O
2	O
.	O
33	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
[	O
26	O
].	O

Proportions	O
with	O
severe	O
anemia	B-DS
(	O
hemoglobin	B-GP
<	O
5g	O
/	O
dL	O
),	O
severe	O
thrombocytopenia	B-DS
(	O
platelet	O
count	O
<	O
50	O
x103	O
/	O
μL	O
)	O
and	O
abnormal	O
white	O
cell	O
count	O
by	O
Plasmodium	B-OG
species	O
.	O

Severe	O
anemia	B-DS

Severe	O
thrombocytopenia	B-DS

White	O
cell	O
count	O

Species	O

Hb	B-GP
≥	O
5g	O
/	O
dL	O
,	O
n	O
(%)	O

Hb	B-GP
<	O
5g	O
/	O
dL	O
,	O
n	O
(%)	O

WHO	O
criteria	O
*,	O
n	O
(%)	O

Plt	O
≥	O
50x103	O
/	O
μL	O
,	O
n	O
(%)	O

Plt	O
<	O
50	O
x103	O
/	O
μL	O
,	O
n	O
(%)	O

Normal	O
,	O
n	O
(%)	O

Abnormal	O
,	O
n	O
(%)	O

Negative	O

163	O
,	O
650	O
(	O
97	O
.	O
5	O
)	O

4	O
,	O
136	O
(	O
2	O
.	O
5	O
)	O

12	O
,	O
051	O
(	O
7	O
.	O
2	O
)	O

159	O
,	O
755	O
(	O
97	O
.	O
3	O
)	O

4	O
,	O
417	O
(	O
2	O
.	O
7	O
)	O

94	O
,	O
929	O
(	O
57	O
.	O
1	O
)	O

71	O
,	O
224	O
(	O
42	O
.	O
9	O
)	O

P	B-OG
.	I-OG
malariae	I-OG

1	O
,	O
650	O
(	O
94	O
.	O
3	O
)	O

100	O
(	O
5	O
.	O
7	O
)	O

250	O
(	O
14	O
.	O
3	O
)	O

1	O
,	O
590	O
(	O
92	O
.	O
8	O
)	O

123	O
(	O
7	O
.	O
2	O
)	O

1	O
,	O
141	O
(	O
65	O
.	O
6	O
)	O

598	O
(	O
34	O
.	O
4	O
)	O

P	B-OG
.	I-OG
falciparum	I-OG

37	O
,	O
585	O
(	O
93	O
.	O
7	O
)	O

2	O
,	O
521	O
(	O
6	O
.	O
3	O
)	O

4	O
,	O
851	O
(	O
12	O
.	O
1	O
)	O

33	O
,	O
353	O
(	O
85	O
.	O
0	O
)	O

5	O
,	O
905	O
(	O
15	O
.	O
0	O
)	O

26	O
,	O
956	O
(	O
67	O
.	O
8	O
)	O

12	O
,	O
812	O
(	O
32	O
.	O
2	O
)	O

P	B-OG
.	I-OG
vivax	I-OG

21	O
,	O
085	O
(	O
95	O
.	O
0	O
)	O

1	O
,	O
099	O
(	O
5	O
.	O
0	O
)	O

1	O
,	O
805	O
(	O
8	O
.	O
1	O
)	O

20	O
,	O
044	O
(	O
92	O
.	O
0	O
)	O

1	O
,	O
743	O
(	O
8	O
.	O
0	O
)	O

15	O
,	O
422	O
(	O
69	O
.	O
9	O
)	O

6	O
,	O
644	O
(	O
30	O
.	O
1	O
)	O

P	B-OG
.	I-OG
ovale	I-OG

31	O
(	O
100	O
)	O

0	O
(	O
0	O
)	O

3	O
(	O
9	O
.	O
7	O
)	O

28	O
(	O
93	O
.	O
3	O
)	O

2	O
(	O
6	O
.	O
7	O
)	O

21	O
(	O
72	O
.	O
4	O
)	O

8	O
(	O
27	O
.	O
6	O
)	O

Mixed	O
species	O

8	O
,	O
955	O
(	O
92	O
.	O
0	O
)	O

782	O
(	O
8	O
.	O
0	O
)	O

1	O
,	O
239	O
(	O
12	O
.	O
7	O
)	O

8	O
,	O
345	O
(	O
87	O
.	O
1	O
)	O

1	O
,	O
231	O
(	O
12	O
.	O
9	O
)	O

6	O
,	O
674	O
(	O
68	O
.	O
9	O
)	O

3	O
,	O
015	O
(	O
31	O
.	O
1	O
)	O

Total	O

232	O
,	O
956	O
(	O
96	O
.	O
4	O
)	O

8	O
,	O
638	O
(	O
3	O
.	O
6	O
)	O

20	O
,	O
199	O
(	O
8	O
.	O
4	O
)	O

223	O
,	O
115	O
(	O
94	O
.	O
3	O
)	O

13	O
,	O
421	O
(	O
5	O
.	O
7	O
)	O

145	O
,	O
143	O
(	O
60	O
.	O
6	O
)	O

94	O
,	O
301	O
(	O
39	O
.	O
4	O
)	O

Abbreviations	O
:	O
n	O
;	O
number	O
,	O
WHO	O
;	O
World	O
Health	O
Organization	O
,	O
Hb	B-GP
;	O
hemoglobin	B-GP
,	O
Plt	O
;	O
platelet	O

*	O
Hemoglobin	B-GP
<	O
5g	O
/	O
dL	O
in	O
children	O
under	O
12	O
years	O
old	O
and	O
<	O
7g	O
/	O
dL	O
in	O
adults	O
≥	O
12	O
years	O
old	O

Univariable	O
and	O
multivariable	O
logistic	O
regression	O
models	O
of	O
the	O
risk	O
factors	O
for	O
severe	O
anemia	B-DS
(	O
hemoglobin	B-GP
<	O
5g	O
/	O
dL	O
)	O
and	O
severe	O
thrombocytopenia	B-DS
(	O
platelet	O
count	O
<	O
50	O
x103	O
/	O
μL	O
).	O

Severe	O
anemia	B-DS
(	O
Hb	B-GP
<	O
5g	O
/	O
dL	O
)	O

Severe	O
thrombocytopenia	B-DS
(	O
Plt	O
<	O
50x103	O
/	O
μL	O
)	O

Risk	O
factor	O

Crude	O
OR	O
(	O
95	O
%	O
CI	O
)	O

P	O

AOR	O
a	O
(	O
95	O
%	O
CI	O
)	O

P	O

Crude	O
OR	O
(	O
95	O
%	O
CI	O
)	O

P	O

AOR	O
a	O
(	O
95	O
%	O
CI	O
)	O

P	O

Species	O

Negative	O

ref	O

-	O

ref	O

-	O

ref	O

-	O

ref	O

-	O

P	B-OG
.	I-OG
malariae	I-OG

2	O
.	O
40	O
(	O
1	O
.	O
94	O
–	O
2	O
.	O
96	O
)	O

<	O
0	O
.	O
001	O

2	O
.	O
29	O
(	O
1	O
.	O
85	O
–	O
2	O
.	O
84	O
)	O

<	O
0	O
.	O
001	O

2	O
.	O
80	O
(	O
2	O
.	O
32	O
–	O
3	O
.	O
38	O
)	O

<	O
0	O
.	O
001	O

2	O
.	O
34	O
(	O
1	O
.	O
93	O
–	O
2	O
.	O
83	O
)	O

<	O
0	O
.	O
001	O

P	B-OG
.	I-OG
falciparum	I-OG

2	O
.	O
65	O
(	O
2	O
.	O
51	O
–	O
2	O
.	O
81	O
)	O

<	O
0	O
.	O
001	O

2	O
.	O
24	O
(	O
2	O
.	O
11	O
–	O
2	O
.	O
38	O
)	O

<	O
0	O
.	O
001	O

6	O
.	O
40	O
(	O
6	O
.	O
07	O
–	O
6	O
.	O
76	O
)	O

<	O
0	O
.	O
001	O

6	O
.	O
20	O
(	O
5	O
.	O
86	O
–	O
6	O
.	O
55	O
)	O

<	O
0	O
.	O
001	O

P	B-OG
.	I-OG
vivax	I-OG

2	O
.	O
06	O
(	O
1	O
.	O
92	O
–	O
2	O
.	O
22	O
)	O

<	O
0	O
.	O
001	O

2	O
.	O
03	O
(	O
1	O
.	O
89	O
–	O
2	O
.	O
19	O
)	O

<	O
0	O
.	O
001	O

3	O
.	O
15	O
(	O
2	O
.	O
94	O
–	O
3	O
.	O
37	O
)	O

<	O
0	O
.	O
001	O

3	O
.	O
88	O
(	O
3	O
.	O
62	O
–	O
4	O
.	O
15	O
)	O

<	O
0	O
.	O
001	O

Mixed	O
species	O

3	O
.	O
46	O
(	O
3	O
.	O
18	O
–	O
3	O
.	O
76	O
)	O

<	O
0	O
.	O
001	O

3	O
.	O
58	O
(	O
3	O
.	O
28	O
–	O
3	O
.	O
91	O
)	O

<	O
0	O
.	O
001	O

5	O
.	O
34	O
(	O
4	O
.	O
95	O
–	O
5	O
.	O
75	O
)	O

<	O
0	O
.	O
001	O

5	O
.	O
86	O
(	O
5	O
.	O
42	O
–	O
6	O
.	O
34	O
)	O

<	O
0	O
.	O
001	O

Age	O
group	O

<	O
1	O
year	O

0	O
.	O
98	O
(	O
0	O
.	O
89	O
–	O
1	O
.	O
08	O
)	O

0	O
.	O
6	O

1	O
.	O
02	O
(	O
0	O
.	O
92	O
–	O
1	O
.	O
12	O
)	O

0	O
.	O
8	O

0	O
.	O
44	O
(	O
0	O
.	O
41	O
–	O
0	O
.	O
48	O
)	O

<	O
0	O
.	O
001	O

0	O
.	O
47	O
(	O
0	O
.	O
43	O
–	O
0	O
.	O
52	O
)	O

<	O
0	O
.	O
001	O

1	O
to	O
<	O
5	O
years	O

1	O
.	O
58	O
(	O
1	O
.	O
48	O
–	O
1	O
.	O
69	O
)	O

<	O
0	O
.	O
001	O

1	O
.	O
25	O
(	O
1	O
.	O
16	O
–	O
1	O
.	O
34	O
)	O

<	O
0	O
.	O
001	O

0	O
.	O
46	O
(	O
0	O
.	O
43	O
–	O
0	O
.	O
49	O
)	O

<	O
0	O
.	O
001	O

0	O
.	O
31	O
(	O
0	O
.	O
28	O
–	O
0	O
.	O
33	O
)	O

<	O
0	O
.	O
001	O

5	O
to	O
<	O
15	O
years	O

1	O
.	O
49	O
(	O
1	O
.	O
37	O
–	O
1	O
.	O
61	O
)	O

<	O
0	O
.	O
001	O

1	O
.	O
15	O
(	O
1	O
.	O
06	O
–	O
1	O
.	O
25	O
)	O

0	O
.	O
001	O

0	O
.	O
80	O
(	O
0	O
.	O
75	O
–	O
0	O
.	O
85	O
)	O

<	O
0	O
.	O
001	O

0	O
.	O
48	O
(	O
0	O
.	O
45	O
–	O
0	O
.	O
51	O
)	O

<	O
0	O
.	O
001	O

≥	O
15	O
years	O

ref	O

-	O

ref	O

-	O

ref	O

-	O

ref	O

-	O

Gender	O

Male	O

ref	O

-	O

ref	O

-	O

ref	O

-	O

ref	O

-	O

Female	O

1	O
.	O
05	O
(	O
0	O
.	O
99	O
–	O
1	O
.	O
11	O
)	O

0	O
.	O
1	O

-	O
b	O

-	O

0	O
.	O
76	O
(	O
0	O
.	O
72	O
–	O
0	O
.	O
79	O
)	O

<	O
0	O
.	O
001	O

-	O
b	O

-	O

Pregnancy	O
status	O

Not	O
pregnant	O

ref	O

-	O

1	O
.	O
17	O
(	O
1	O
.	O
10	O
–	O
1	O
.	O
24	O
)	O
b	O

<	O
0	O
.	O
001	O

ref	O

-	O

0	O
.	O
75	O
(	O
0	O
.	O
71	O
–	O
0	O
.	O
79	O
)	O
b	O

<	O
0	O
.	O
001	O

Pregnant	O

0	O
.	O
62	O
(	O
0	O
.	O
57	O
–	O
0	O
.	O
68	O
)	O

<	O
0	O
.	O
001	O

0	O
.	O
99	O
(	O
0	O
.	O
89	O
–	O
1	O
.	O
10	O
)	O
b	O

0	O
.	O
9	O

0	O
.	O
65	O
(	O
0	O
.	O
60	O
–	O
0	O
.	O
71	O
)	O

<	O
0	O
.	O
001	O

0	O
.	O
61	O
(	O
0	O
.	O
55	O
–	O
0	O
.	O
66	O
)	O
b	O

<	O
0	O
.	O
001	O

Ethnic	O
Group	O

Non	O
-	O
Papuan	O

ref	O

-	O

ref	O

-	O

ref	O

-	O

ref	O

-	O

Highland	O
Papuan	O

4	O
.	O
22	O
(	O
3	O
.	O
75	O
–	O
4	O
.	O
74	O
)	O

<	O
0	O
.	O
001	O

3	O
.	O
89	O
(	O
3	O
.	O
45	O
–	O
4	O
.	O
38	O
)	O

<	O
0	O
.	O
001	O

3	O
.	O
06	O
(	O
2	O
.	O
83	O
–	O
3	O
.	O
30	O
)	O

<	O
0	O
.	O
001	O

2	O
.	O
89	O
(	O
2	O
.	O
66	O
–	O
3	O
.	O
14	O
)	O

<	O
0	O
.	O
001	O

Lowland	O
Papuan	O

2	O
.	O
64	O
(	O
2	O
.	O
30	O
–	O
3	O
.	O
04	O
)	O

<	O
0	O
.	O
001	O

2	O
.	O
52	O
(	O
2	O
.	O
18	O
–	O
2	O
.	O
91	O
)	O

<	O
0	O
.	O
001	O

0	O
.	O
87	O
(	O
0	O
.	O
78	O
–	O
0	O
.	O
97	O
)	O

0	O
.	O
02	O

0	O
.	O
99	O
(	O
0	O
.	O
89	O
–	O
1	O
.	O
12	O
)	O

0	O
.	O
9	O

White	O
cell	O
count	O

Normal	O

ref	O

-	O

ref	O

-	O

ref	O

-	O

ref	O

-	O

Abnormal	O

1	O
.	O
85	O
(	O
1	O
.	O
77	O
–	O
1	O
.	O
94	O
)	O

<	O
0	O
.	O
001	O

2	O
.	O
07	O
(	O
1	O
.	O
97	O
–	O
2	O
.	O
18	O
)	O

<	O
0	O
.	O
001	O

1	O
.	O
34	O
(	O
1	O
.	O
29	O
–	O
1	O
.	O
39	O
)	O

<	O
0	O
.	O
001	O

1	O
.	O
77	O
(	O
1	O
.	O
70	O
–	O
1	O
.	O
85	O
)	O

<	O
0	O
.	O
001	O

Abbreviations	O
:	O
OR	O
;	O
odds	O
ratio	O
,	O
AOR	O
;	O
adjusted	O
odds	O
ratio	O
,	O
Hb	B-GP
;	O
hemoglobin	B-GP
,	O
Plt	O
;	O
platelet	O

a	O
Multivariable	O
models	O
also	O
include	O
year	O
of	O
presentation	O

b	O
In	O
the	O
multivariable	O
model	O
,	O
a	O
non	O
-	O
ordered	O
,	O
3	O
-	O
category	O
variable	O
incorporating	O
sex	O
and	O
pregnancy	O
status	O
was	O
used	O
.	O

Male	O
sex	O
is	O
the	O
reference	O
category	O
.	O

The	O
mean	O
platelet	O
count	O
in	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
was	O
142	O
.	O
7x103	O
/	O
μL	O
,	O
compared	O
to	O
130	O
.	O
4x103	O
/	O
μL	O
for	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
166	O
.	O
8x103	O
/	O
μL	O
for	O
P	B-OG
.	I-OG
vivax	I-OG
and	O
131	O
.	O
6x103	O
/	O
μL	O
for	O
mixed	O
species	O
infection	B-DS
.	O

Severe	O
thrombocytopenia	B-DS
(	O
platelet	O
count	O
<	O
50x103	O
/	O
μL	O
)	O
was	O
present	O
in	O
123	O
(	O
7	O
.	O
2	O
%)	O
patients	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
(	O
Table	O
3	O
)	O
and	O
very	O
severe	O
thrombocytopenia	B-DS
(	O
platelet	O
count	O
<	O
20x103	O
/	O
μL	O
)	O
in	O
16	O
(	O
0	O
.	O
9	O
%)	O
cases	O
.	O

None	O
of	O
the	O
patients	O
with	O
platelet	O
counts	O
<	O
50x103	O
/	O
μL	O
)	O
were	O
recorded	O
as	O
having	O
clinical	O
evidence	O
of	O
bleeding	O
.	O

After	O
controlling	O
for	O
confounding	O
factors	O
,	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
was	O
associated	O
with	O
a	O
two	O
-	O
fold	O
higher	O
odds	O
of	O
severe	O
thrombocytopenia	B-DS
compared	O
to	O
those	O
with	O
no	O
malaria	B-DS
(	O
AOR	O
;	O
2	O
.	O
34	O
,	O
95	O
%	O
CI	O
;	O
1	O
.	O
93	O
–	O
2	O
.	O
83	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
(	O
Table	O
4	O
).	O

Overall	O
34	O
.	O
4	O
%	O
(	O
n	O
=	O
598	O
)	O
of	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
had	O
an	O
abnormal	O
age	O
-	O
adjusted	O
white	O
cell	O
count	O
;	O
a	O
similar	O
proportion	O
to	O
patients	O
infected	O
with	O
the	O
other	O
Plasmodium	B-OG
species	O
,	O
but	O
lower	O
than	O
that	O
in	O
patients	O
without	O
malaria	B-DS
(	O
42	O
.	O
9	O
%,	O
P	O
<	O
0	O
.	O
001	O
).	O

In	O
36	O
.	O
8	O
%	O
of	O
cases	O
the	O
abnormal	O
white	O
cell	O
count	O
was	O
above	O
the	O
age	O
-	O
adjusted	O
normal	O
range	O
and	O
in	O
the	O
remaining	O
63	O
.	O
2	O
%	O
it	O
was	O
below	O
the	O
normal	O
range	O
.	O

Mortality	O

In	O
total	O
,	O
0	O
.	O
3	O
%	O
(	O
16	O
/	O
5	O
,	O
097	O
)	O
of	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
died	O
compared	O
to	O
0	O
.	O
5	O
%	O
(	O
4	O
,	O
254	O
/	O
858	O
,	O
294	O
)	O
of	O
those	O
without	O
malaria	B-DS
,	O
0	O
.	O
4	O
%	O
(	O
376	O
/	O
100	O
,	O
078	O
)	O
with	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
0	O
.	O
2	O
%	O
(	O
130	O
/	O
65	O
,	O
306	O
)	O
with	O
P	B-OG
.	I-OG
vivax	I-OG
,	O
none	O
with	O
P	B-OG
.	I-OG
ovale	I-OG
and	O
0	O
.	O
3	O
%	O
(	O
73	O
/	O
25	O
,	O
779	O
)	O
with	O
mixed	B-DS
infections	I-DS
.	O

The	O
corresponding	O
risk	O
of	O
mortality	O
for	O
patients	O
who	O
were	O
admitted	O
to	O
hospital	O
or	O
seen	O
in	O
the	O
emergency	O
department	O
was	O
2	O
.	O
4	O
%	O
(	O
16	O
/	O
663	O
)	O
for	O
P	B-OG
.	I-OG
malariae	I-OG
,	O
3	O
.	O
4	O
%	O
(	O
4	O
,	O
244	O
/	O
125	O
,	O
375	O
)	O
for	O
those	O
without	O
Plasmodium	B-OG
infection	B-DS
,	O
1	O
.	O
6	O
%	O
(	O
375	O
/	O
23	O
,	O
304	O
)	O
for	O
P	B-OG
.	I-OG
falciparum	I-OG
,	O
1	O
.	O
4	O
%	O
(	O
129	O
/	O
8	O
,	O
937	O
)	O
for	O
P	B-OG
.	I-OG
vivax	I-OG
and	O
1	O
.	O
6	O
%	O
(	O
73	O
/	O
4	O
,	O
608	O
)	O
for	O
mixed	B-DS
infections	I-DS
.	O

The	O
median	O
age	O
of	O
the	O
16	O
patients	O
who	O
died	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
parasitemia	I-DS
was	O
23	O
.	O
4	O
years	O
(	O
Range	O
;	O
5	O
.	O
6	O
to	O
50	O
years	O
,	O
IQR	O
;	O
17	O
.	O
0	O
–	O
41	O
.	O
9	O
years	O
),	O
with	O
a	O
risk	O
of	O
mortality	O
of	O
1	O
/	O
1	O
,	O
481	O
(	O
0	O
.	O
07	O
%)	O
in	O
children	O
<	O
12	O
years	O
and	O
15	O
/	O
3	O
,	O
616	O
(	O
0	O
.	O
4	O
%)	O
in	O
adults	O
≥	O
12	O
years	O
.	O

Nine	O
(	O
56	O
.	O
3	O
%)	O
of	O
the	O
patients	O
who	O
died	O
were	O
male	O
,	O
4	O
(	O
26	O
.	O
7	O
%)	O
had	O
a	O
hemoglobin	B-GP
<	O
5g	O
/	O
dL	O
and	O
6	O
(	O
40	O
%)	O
had	O
severe	O
anemia	B-DS
according	O
to	O
2014	O
WHO	O
criteria	O
(	O
Table	O
5	O
).	O

Two	O
patients	O
(	O
14	O
.	O
3	O
%)	O
had	O
severe	O
thrombocytopenia	B-DS
and	O
10	O
(	O
71	O
.	O
4	O
%)	O
had	O
an	O
abnormal	O
white	O
cell	O
count	O
(	O
9	O
patients	O
(	O
90	O
%)	O
had	O
a	O
value	O
that	O
was	O
above	O
the	O
normal	O
range	O
during	O
their	O
admission	O
and	O
three	O
(	O
30	O
%)	O
had	O
a	O
value	O
that	O
was	O
below	O
the	O
normal	O
range	O
).	O

Five	O
(	O
31	O
%)	O
patients	O
were	O
recorded	O
as	O
having	O
concomitant	O
tuberculosis	B-DS
.	O

Hematological	O
parameters	O
and	O
recorded	O
comorbidities	O
in	O
the	O
16	O
patients	O
who	O
died	O
with	O
Plasmodium	B-OG
malariae	I-OG
parasitemia	B-DS
.	O

Patient	O
Number	O

Sex	O

Age	O
(	O
years	O
)	O

Length	O
of	O
stay	O
(	O
days	O
)	O

Minimum	O
hemoglobin	B-GP
concentration	O
(	O
g	O
/	O
dL	O
)	O

Platelet	O
count	O
(	O
x103	O
/	O
μL	O
)	O

Most	O
abnormal	O
white	O
cell	O
count	O
(	O
cells	O
/	O
μL	O
)	O

Other	O
recorded	O
diagnoses	O

1	O
.	O

M	O

33	O
.	O
7	O

6	O

2	O
.	O
7	O

146	O

6	O
,	O
100	O

Ischaemic	B-DS
cardiomyopathy	I-DS

Congestive	B-DS
heart	I-DS
failure	I-DS

Non	O
-	O
inflammatory	O
pericardial	B-DS
effusion	I-DS

Pneumonia	B-DS

2	O
.	O

M	O

22	O
.	O
6	O

13	O

9	O
.	O
6	O

182	O

2	O
,	O
600	O

HIV	B-OG

Tuberculous	O
meningitis	O

Gastroenteritis	B-DS

3	O
.	O

M	O

37	O
.	O
6	O

0	O
.	O
5	O

11	O
.	O
1	O

343	O

16	O
,	O
800	O

Pulmonary	B-DS
tuberculosis	I-DS

4	O
.	O

M	O

21	O
.	O
3	O

9	O

3	O
.	O
1	O

53	O

13	O
,	O
100	O

Acute	B-DS
renal	I-DS
failure	I-DS

5	O
.	O

F	O

12	O
.	O
2	O

3	O

7	O
.	O
8	O

199	O

29	O
,	O
000	O

Malnutrition	B-DS

Helminthiasis	B-DS

Pulmonary	B-DS
tuberculosis	I-DS

6	O
.	O

F	O

18	O

0	O
.	O
5	O

-	O

-	O

-	O

-	O

7	O
.	O

F	O

18	O
.	O
7	O

1	O

11	O
.	O
9	O

93	O

10	O
,	O
500	O

Pulmonary	B-DS
tuberculosis	I-DS

Gastroenteritis	B-DS

Urinary	O
tract	O
infection	B-DS

8	O
.	O

F	O

12	O

0	O
.	O
5	O

3	O
.	O
3	O

-	O

15	O
,	O
600	O

-	O

9	O
.	O

M	O

49	O
.	O
1	O

0	O
.	O
5	O

6	O
.	O
7	O

23	O

14	O
,	O
700	O

Pneumonia	B-DS

Non	O
-	O
infective	O
gastroenteritis	B-DS

Chronic	B-DS
renal	I-DS
failure	I-DS

10	O
.	O

F	O

46	O
.	O
1	O

1	O

11	O

44	O

4	O
,	O
100	O

Pulmonary	B-DS
tuberculosis	I-DS

Gastroenteritis	B-DS

11	O
.	O

F	O

16	O

6	O

4	O
.	O
8	O

339	O

13	O
,	O
200	O

Chronic	B-DS
renal	I-DS
failure	I-DS

12	O
.	O

M	O

24	O
.	O
1	O

0	O

7	O
.	O
2	O

140	O

6	O
,	O
000	O

-	O

Pneumonia	B-DS

Adult	O
Respiratory	O
Distress	O
Syndrome	O

14	O
.	O

M	O

50	O

1	O

6	O
.	O
9	O

128	O

8	O
,	O
300	O

Pneumonia	B-DS

Chronic	B-DS
renal	I-DS
failure	I-DS

Suspected	O
tuberculosis	B-DS

Inguinal	B-DS
hernia	I-DS

Ascites	O

15	O
.	O

M	O

5	O
.	O
6	O

3	O

11	O
.	O
1	O

56	O

3	O
,	O
500	O

Encephalomyelitis	O

16	O
.	O

F	O

48	O

0	O

10	O
.	O
6	O

156	O

-	O

-	O

Abbreviations	O
:	O
F	O
=	O
female	O
,	O
M	O
=	O
male	O

Discussion	O

This	O
large	O
case	O
series	O
from	O
southern	O
Papua	O
shows	O
that	O
P	B-OG
.	I-OG
malariae	I-OG
is	O
responsible	O
for	O
a	O
minority	O
(	O
2	O
.	O
6	O
%)	O
of	O
clinical	O
malaria	B-DS
cases	O
but	O
has	O
potential	O
to	O
cause	O
significant	O
morbidity	O
.	O

Compared	O
to	O
patients	O
infected	O
with	O
other	O
Plasmodium	B-OG
species	O
,	O
those	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
had	O
a	O
lower	O
mean	O
hemoglobin	B-GP
concentration	O
and	O
a	O
similar	O
risk	O
of	O
being	O
admitted	O
to	O
hospital	O
(	O
8	O
.	O
5	O
%)	O
or	O
dying	O
(	O
0	O
.	O
3	O
%).	O

Overall	O
P	B-OG
.	I-OG
malariae	I-OG
malaria	B-DS
accounted	O
for	O
almost	O
0	O
.	O
5	O
%	O
of	O
hospital	O
bed	O
occupancy	O
.	O

Patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infections	I-DS
tended	O
to	O
be	O
older	O
than	O
those	O
with	O
non	O
P	B-OG
.	I-OG
malariae	I-OG
malaria	B-DS
,	O
particularly	O
compared	O
to	O
those	O
with	O
P	B-OG
.	I-OG
vivax	I-OG
mono	O
-	O
or	O
mixed	B-DS
infections	I-DS
.	O

This	O
probably	O
reflects	O
the	O
low	O
transmission	O
intensity	O
in	O
this	O
area	O
.	O

Whereas	O
the	O
majority	O
of	O
children	O
in	O
Timika	O
are	O
likely	O
to	O
have	O
been	O
infected	O
with	O
P	B-OG
.	I-OG
vivax	I-OG
by	O
the	O
age	O
of	O
5	O
years	O
(	O
and	O
therefore	O
have	O
started	O
to	O
acquire	O
immunity	O
early	O
in	O
life	O
),	O
fewer	O
than	O
one	O
in	O
ten	O
children	O
could	O
be	O
expected	O
to	O
have	O
been	O
infected	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
by	O
the	O
same	O
age	O
(	O
based	O
on	O
an	O
estimated	O
annual	O
incidence	O
of	O
15	O
.	O
7	O
cases	O
per	O
1	O
,	O
000	O
persons	O
in	O
2005	O
)	O
[	O
20	O
].	O
Plasmodium	B-OG
malariae	I-OG
has	O
a	O
predilection	O
for	O
senescent	O
red	O
blood	O
cells	O
whereas	O
P	B-OG
.	I-OG
vivax	I-OG
preferentially	O
infects	O
young	O
red	O
cells	O
,	O
in	O
particular	O
reticulocytes	O
[	O
28	O
,	O
29	O
].	O

It	O
is	O
therefore	O
possible	O
that	O
during	O
the	O
very	O
early	O
stages	O
of	O
infancy	O
there	O
is	O
a	O
biological	O
predisposition	O
to	O
vivax	B-DS
malaria	I-DS
and	O
a	O
relative	O
protection	O
against	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
.	O

A	O
major	O
finding	O
of	O
our	O
study	O
(	O
and	O
one	O
that	O
was	O
also	O
noted	O
in	O
an	O
earlier	O
published	O
analysis	O
from	O
this	O
region	O
[	O
24	O
])	O
is	O
the	O
association	O
between	O
P	B-DS
.	I-DS
malariae	I-DS
parasitemia	I-DS
and	O
substantial	O
hematological	O
morbidity	O
.	O

The	O
mean	O
hemoglobin	B-GP
in	O
patients	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
was	O
0	O
.	O
3	O
–	O
0	O
.	O
6g	O
/	O
dL	O
lower	O
than	O
the	O
other	O
locally	O
prevalent	O
Plasmodium	B-OG
species	O
with	O
an	O
associated	O
2	O
.	O
3	O
-	O
fold	O
greater	O
odds	O
of	O
severe	O
anemia	B-DS
compared	O
to	O
individuals	O
without	O
malaria	B-DS
.	O

There	O
are	O
several	O
potential	O
explanations	O
for	O
this	O
finding	O
.	O
Plasmodium	B-OG
malariae	I-OG
replicates	O
slowly	O
and	O
does	O
not	O
typically	O
reach	O
high	O
parasitemias	B-DS
[	O
29	O
].	O

Prolonged	O
infection	B-DS
is	O
therefore	O
more	O
likely	O
to	O
have	O
been	O
present	O
in	O
patients	O
presenting	O
with	O
this	O
disease	O
compared	O
to	O
those	O
with	O
P	B-OG
.	I-OG
falciparum	I-OG
or	O
P	B-DS
.	I-DS
vivax	I-DS
infections	I-DS
.	O

A	O
chronic	O
,	O
low	O
-	O
level	O
parasitemia	B-DS
resulting	O
in	O
ongoing	O
destruction	O
of	O
both	O
parasitized	O
but	O
,	O
more	O
importantly	O
,	O
non	O
-	O
parasitized	O
red	O
cells	O
as	O
well	O
as	O
marrow	O
dyserythropoiesis	B-DS
may	O
have	O
a	O
cumulative	O
effect	O
on	O
lowering	O
hemoglobin	B-GP
concentrations	O
.	O

Previous	O
observation	O
of	O
malariatherapy	O
patients	O
treated	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
demonstrated	O
that	O
those	O
with	O
naturally	O
-	O
induced	O
infections	B-DS
typically	O
had	O
a	O
nadir	O
in	O
hemoglobin	B-GP
concentration	O
between	O
day	O
30	O
and	O
90	O
of	O
infection	B-DS
with	O
only	O
a	O
slight	O
improvement	O
in	O
concentrations	O
thereafter	O
[	O
16	O
].	O

Recent	O
data	O
suggest	O
that	O
the	O
low	O
circulating	O
parasitemias	B-DS
found	O
in	O
P	B-DS
.	I-DS
vivax	I-DS
infection	I-DS
significantly	O
underestimate	O
total	O
parasite	O
biomass	O
[	O
30	O
].	O

While	O
speculative	O
,	O
it	O
is	O
possible	O
that	O
a	O
hidden	O
,	O
non	O
-	O
circulating	O
parasite	O
biomass	O
may	O
also	O
be	O
present	O
in	O
P	B-OG
.	I-OG
malariae	I-OG
,	O
capable	O
of	O
contributing	O
to	O
a	O
degree	O
of	O
anemia	B-DS
out	O
of	O
proportion	O
to	O
circulating	O
parasitemia	B-DS
.	O

It	O
is	O
also	O
possible	O
that	O
the	O
significant	O
anemia	B-DS
seen	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
is	O
partially	O
a	O
result	O
of	O
comorbid	O
conditions	O
as	O
opposed	O
to	O
the	O
infection	B-DS
itself	O
.	O

However	O
,	O
given	O
the	O
similar	O
frequency	O
of	O
major	O
comorbidities	O
such	O
as	O
pneumonia	B-DS
,	O
renal	B-DS
disease	I-DS
and	O
HIV	B-OG
compared	O
with	O
the	O
other	O
species	O
,	O
a	O
major	O
bias	O
from	O
differential	O
rates	O
of	O
comorbidities	O
seems	O
unlikely	O
.	O

Finally	O
,	O
Highland	O
Papuans	O
are	O
the	O
ethnic	O
group	O
with	O
the	O
highest	O
risk	O
of	O
severe	O
anemia	B-DS
in	O
Timika	O
–	O
possibly	O
due	O
to	O
nutritional	O
factors	O
,	O
red	O
cell	O
and	O
hemoglobin	B-GP
abnormalities	O
or	O
gastrointestinal	O
helminth	B-DS
infection	I-DS
.	O

Whether	O
for	O
geographical	O
or	O
biological	O
reasons	O
,	O
a	O
particularly	O
high	O
proportion	O
of	O
P	B-OG
.	I-OG
malariae	I-OG
patients	O
were	O
highlanders	O
,	O
potentially	O
contributing	O
to	O
the	O
lower	O
mean	O
hemoglobin	B-GP
seen	O
in	O
these	O
patients	O
.	O

After	O
adjusting	O
for	O
various	O
risk	O
factors	O
,	O
including	O
ethnicity	O
,	O
in	O
the	O
multivariable	O
model	O
,	O
the	O
risk	O
of	O
severe	O
anemia	B-DS
in	O
P	B-DS
.	I-DS
malariae	I-DS
infections	I-DS
was	O
similar	O
to	O
that	O
for	O
P	B-OG
.	I-OG
falciparum	I-OG
and	O
P	B-OG
.	I-OG
vivax	I-OG
monoinfections	O
.	O

The	O
low	O
incidence	O
of	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
and	O
relatively	O
high	O
burden	O
of	O
falciparum	B-OG
and	O
vivax	B-DS
malaria	I-DS
means	O
that	O
the	O
latter	O
species	O
are	O
more	O
common	O
causes	O
of	O
severe	O
anemia	B-DS
and	O
therefore	O
more	O
important	O
targets	O
for	O
public	O
health	O
intervention	O
.	O

Nevertheless	O
,	O
on	O
an	O
individual	O
basis	O
,	O
those	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
parasitemia	I-DS
need	O
to	O
be	O
investigated	O
for	O
anemia	B-DS
and	O
treated	O
aggressively	O
if	O
present	O
.	O

In	O
this	O
context	O
,	O
the	O
relatively	O
high	O
rates	O
of	O
representation	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
over	O
the	O
subsequent	O
year	O
(~	O
4	O
%),	O
raises	O
the	O
possibility	O
of	O
partial	O
response	O
to	O
ACT	O
treatment	O
coupled	O
with	O
prolonged	O
subclinical	O
carriage	O
.	O

There	O
have	O
been	O
few	O
studies	O
of	O
ACT	O
drug	O
efficacy	O
in	O
P	B-OG
.	I-OG
malariae	I-OG
and	O
most	O
have	O
had	O
only	O
28	O
days	O
of	O
follow	O
-	O
up	O
[	O
31	O
].	O

Further	O
efficacy	O
studies	O
with	O
longer	O
follow	O
-	O
up	O
are	O
warranted	O
.	O

Nephrotic	B-DS
syndrome	I-DS
,	O
a	O
well	O
-	O
recognized	O
complication	O
of	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
,	O
is	O
mostly	O
described	O
in	O
children	O
living	O
in	O
endemic	O
areas	O
[	O
32	O
]	O
with	O
few	O
cases	O
reported	O
since	O
the	O
mid	O
-	O
1970s	O
[	O
32	O
–	O
34	O
].	O

Renal	O
biopsies	O
in	O
two	O
recent	O
cases	O
have	O
shown	O
chronic	B-DS
membranous	I-DS
glomerulopathy	I-DS
[	O
34	O
]	O
and	O
mesangioproliferative	O
glomerulonephritis	B-DS
respectively	O
[	O
33	O
].	O

The	O
syndrome	O
has	O
been	O
reported	O
as	O
being	O
hard	O
to	O
treat	O
and	O
often	O
unresponsive	O
to	O
corticosteroids	O
,	O
immunosuppressive	O
agents	O
and	O
antimalarial	O
drugs	O
[	O
35	O
].	O

Given	O
the	O
lack	O
of	O
access	O
to	O
advanced	O
diagnostic	O
techniques	O
in	O
Timika	O
,	O
the	O
diagnoses	O
of	O
nephrotic	B-DS
syndrome	I-DS
must	O
be	O
treated	O
with	O
caution	O
.	O

Moreover	O
,	O
we	O
cannot	O
infer	O
that	O
there	O
was	O
necessarily	O
a	O
causal	O
relationship	O
between	O
the	O
P	B-DS
.	I-DS
malariae	I-DS
infections	I-DS
and	O
nephrotic	B-DS
syndrome	I-DS
.	O

Nevertheless	O
,	O
we	O
have	O
,	O
for	O
the	O
first	O
time	O
been	O
able	O
to	O
estimate	O
the	O
risk	O
of	O
this	O
condition	O
at	O
1	O
in	O
200	O
presentations	O
to	O
hospital	O
for	O
children	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
under	O
the	O
age	O
of	O
5	O
years	O
.	O

None	O
of	O
the	O
4	O
patients	O
with	O
nephrotic	B-DS
syndrome	I-DS
and	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
were	O
reported	O
to	O
have	O
died	O
during	O
the	O
follow	O
-	O
up	O
period	O
however	O
3	O
of	O
the	O
16	O
patients	O
who	O
died	O
were	O
recorded	O
as	O
having	O
chronic	B-DS
renal	I-DS
failure	I-DS
(	O
not	O
further	O
specified	O
)	O
and	O
one	O
had	O
acute	B-DS
renal	I-DS
failure	I-DS
.	O

Unfortunately	O
we	O
did	O
not	O
have	O
access	O
to	O
information	O
on	O
the	O
presence	O
or	O
absence	O
of	O
albuminuria	B-DS
(	O
a	O
common	O
finding	O
in	O
malariatherapy	O
patients	O
treated	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infections	I-DS
in	O
the	O
1930s	O
[	O
16	O
]).	O

A	O
similar	O
proportion	O
of	O
all	O
patients	O
presenting	O
to	O
hospital	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
died	O
as	O
compared	O
to	O
patients	O
with	O
infection	B-DS
by	O
the	O
other	O
Plasmodium	B-OG
species	O
–	O
a	O
surprising	O
finding	O
given	O
the	O
supposedly	O
low	O
virulence	O
of	O
this	O
species	O
.	O

The	O
same	O
was	O
true	O
of	O
the	O
subset	O
of	O
patients	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
who	O
were	O
admitted	O
to	O
hospital	O
.	O

Based	O
on	O
the	O
data	O
at	O
hand	O
,	O
we	O
cannot	O
make	O
inferences	O
on	O
whether	O
there	O
was	O
a	O
causal	O
link	O
between	O
the	O
P	B-DS
.	I-DS
malariae	I-DS
infections	I-DS
and	O
death	O
.	O

Fourteen	O
of	O
the	O
deceased	O
patients	O
had	O
a	O
white	O
cell	O
count	O
measurement	O
during	O
their	O
final	O
admission	O
and	O
in	O
9	O
cases	O
,	O
this	O
was	O
above	O
the	O
age	O
-	O
appropriate	O
normal	O
range	O
.	O

We	O
were	O
unable	O
to	O
find	O
data	O
on	O
the	O
typical	O
impact	O
of	O
P	B-DS
.	I-DS
malariae	I-DS
infection	I-DS
on	O
white	O
cell	O
counts	O
.	O

The	O
high	O
proportion	O
of	O
the	O
deceased	O
patients	O
with	O
leucocytosis	B-DS
could	O
reflect	O
the	O
greater	O
inflammatory	O
response	O
seen	O
in	O
severe	O
malaria	B-DS
from	O
all	O
species	O
[	O
30	O
,	O
36	O
]	O
and	O
/	O
or	O
concomitant	O
bacterial	B-DS
sepsis	I-DS
.	O

Bacterial	O
coinfection	B-DS
was	O
certainly	O
recorded	O
in	O
several	O
cases	O
.	O

Severe	O
anemia	B-DS
was	O
only	O
present	O
in	O
a	O
quarter	O
of	O
the	O
patients	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
who	O
died	O
(	O
40	O
%	O
if	O
WHO	O
criteria	O
were	O
used	O
)	O
and	O
thus	O
was	O
not	O
the	O
sole	O
attributable	O
cause	O
of	O
death	O
.	O

Plasmodium	B-OG
malariae	I-OG
’	O
s	O
tendency	O
to	O
cause	O
prolonged	O
asymptomatic	O
and	O
/	O
or	O
subpatent	O
infections	B-DS
will	O
confound	O
elimination	O
strategies	O
that	O
are	O
based	O
on	O
active	O
case	O
detection	O
or	O
mass	O
screening	O
and	O
treatment	O
.	O

Chronically	O
infected	O
patients	O
with	O
low	O
-	O
level	O
parasitemia	B-DS
probably	O
have	O
substantial	O
transmission	O
potential	O
and	O
therefore	O
mass	O
drug	O
administration	O
campaigns	O
could	O
potentially	O
have	O
a	O
significant	O
impact	O
on	O
this	O
species	O
.	O

Given	O
the	O
older	O
age	O
distribution	O
of	O
patients	O
infected	O
with	O
P	B-OG
.	I-OG
malariae	I-OG
,	O
it	O
would	O
be	O
important	O
to	O
deliver	O
the	O
antimalarial	O
drug	O
to	O
all	O
age	O
groups	O
rather	O
than	O
just	O
children	O
.	O

Some	O
important	O
limitations	O
of	O
our	O
study	O
should	O
be	O
considered	O
.	O

Malaria	B-DS
diagnosis	O
and	O
species	O
identification	O
was	O
based	O
on	O
microscopy	O
alone	O
(	O
except	O
for	O
a	O
small	O
number	O
of	O
P	B-OG
.	I-OG
falciparum	I-OG
cases	O
confirmed	O
using	O
rapid	O
diagnostic	O
tests	O
),	O
and	O
parasitemia	B-DS
quantitation	O
was	O
not	O
available	O
.	O

Previous	O
studies	O
have	O
clearly	O
demonstrated	O
that	O
microscopic	O
diagnosis	O
of	O
P	B-OG
.	I-OG
malariae	I-OG
significantly	O
underestimates	O
the	O
true	O
prevalence	O
of	O
parasitemia	B-DS
when	O
compared	O
with	O
PCR	O
-	O
based	O
diagnosis	O
and	O
that	O
correctly	O
differentiating	O
between	O
P	B-OG
.	I-OG
malariae	I-OG
and	O
P	B-OG
.	I-OG
falciparum	I-OG
based	O
on	O
morphology	O
alone	O
is	O
fraught	O
with	O
error	O
[	O
37	O
,	O
38	O
].	O

A	O
previous	O
comparison	O
between	O
hospital	O
and	O
research	O
laboratory	O
microscopy	O
results	O
at	O
RSMM	O
showed	O
68	O
.	O
4	O
%	O
concordance	O
in	O
the	O
diagnosis	O
of	O
P	B-OG
.	I-OG
malariae	I-OG
monoinfection	O
with	O
5	O
.	O
3	O
%	O
of	O
P	B-OG
.	I-OG
malariae	I-OG
cases	O
actually	O
deemed	O
to	O
be	O
mixed	O
P	B-OG
.	I-OG
malariae	I-OG
/	O
P	B-DS
.	I-DS
falciparum	I-DS
infections	I-DS
and	O
26	O
.	O
3	O
%	O
of	O
cases	O
originally	O
diagnosed	O
as	O
mixed	O
P	B-DS
.	I-DS
malariae	I-DS
infections	I-DS
reclassified	O
as	O
P	B-OG
.	I-OG
malariae	I-OG
monoinfections	O
[	O
21	O
].	O
Plasmodium	B-DS
malariae	I-DS
infection	I-DS
is	O
often	O
asymptomatic	O
or	O
minimally	O
symptomatic	O
,	O
it	O
is	O
therefore	O
likely	O
that	O
a	O
smaller	O
proportion	O
of	O
individuals	O
infected	O
with	O
this	O
species	O
in	O
the	O
community	O
presented	O
to	O
hospital	O
for	O
assessment	O
and	O
treatment	O
when	O
compared	O
to	O
infections	B-DS
by	O
the	O
other	O
Plasmodium	B-OG
species	O
.	O

A	O
potentially	O
large	O
ascertainment	O
bias	O
will	O
therefore	O
have	O
occurred	O
leading	O
to	O
an	O
underestimation	O
of	O
the	O
true	O
prevalence	O
and	O
burden	O
of	O
P	B-DS
.	I-DS
malariae	I-DS
parasitemia	I-DS
in	O
this	O
region	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
subpatent	O
infection	B-DS
with	O
Plasmodium	B-OG
species	O
is	O
associated	O
with	O
under	O
-	O
recognised	O
morbidity	O
(	O
as	O
well	O
as	O
ongoing	O
risk	O
of	O
transmission	O
),	O
mostly	O
in	O
the	O
form	O
of	O
chronic	B-DS
anemia	I-DS
[	O
39	O
–	O
42	O
].	O

The	O
small	O
fee	O
charged	O
to	O
non	O
-	O
Papuans	O
for	O
care	O
may	O
have	O
discouraged	O
them	O
from	O
accessing	O
the	O
hospital	O
services	O
resulting	O
in	O
a	O
degree	O
of	O
selection	O
bias	O
in	O
our	O
study	O
.	O

Consequently	O
those	O
of	O
Papuan	O
ethnicity	O
were	O
undoubtedly	O
over	O
-	O
represented	O
.	O

Selection	O
bias	O
is	O
also	O
likely	O
to	O
have	O
occurred	O
in	O
our	O
analysis	O
of	O
hematological	O
parameters	O
as	O
hemoglobin	B-GP
measurements	O
were	O
done	O
according	O
to	O
the	O
orders	O
of	O
the	O
treating	O
clinician	O
rather	O
than	O
routinely	O
in	O
all	O
patients	O
.	O

Patients	O
without	O
malaria	B-DS
were	O
less	O
likely	O
to	O
have	O
had	O
a	O
full	O
blood	O
count	O
.	O

Since	O
those	O
who	O
did	O
not	O
have	O
a	O
full	O
blood	O
count	O
were	O
presumably	O
less	O
likely	O
to	O
have	O
been	O
severely	O
anaemic	O
,	O
our	O
analyses	O
will	O
have	O
underestimated	O
the	O
relative	O
impact	O
of	O
malaria	B-DS
on	O
hemoglobin	B-GP
concentrations	O
in	O
the	O
study	O
population	O
.	O

In	O
exploring	O
the	O
anemia	B-DS
associated	O
with	O
Plasmodium	B-OG
infection	B-DS
we	O
were	O
unable	O
to	O
control	O
for	O
some	O
potentially	O
important	O
confounders	O
.	O

We	O
had	O
no	O
information	O
on	O
parasite	O
quantitation	O
/	O
parasite	O
biomass	O
,	O
the	O
prevalence	O
of	O
hemoglobinopathies	B-DS
and	O
red	B-DS
cell	I-DS
disorders	I-DS
such	O
as	O
G6PD	B-DS
deficiency	I-DS
or	O
thalassemia	B-DS
and	O
we	O
were	O
unable	O
to	O
control	O
for	O
factors	O
such	O
as	O
malnutrition	B-DS
,	O
iron	B-DS
deficiency	I-DS
and	O
worm	B-DS
infestation	I-DS
,	O
all	O
of	O
which	O
are	O
known	O
to	O
contribute	O
significantly	O
to	O
anemia	B-DS
[	O
43	O
,	O
44	O
].	O

It	O
is	O
highly	O
probable	O
that	O
some	O
of	O
the	O
anemia	B-DS
detected	O
in	O
those	O
with	O
P	B-DS
.	I-DS
malariae	I-DS
parasitemia	I-DS
was	O
contributed	O
to	O
by	O
these	O
factors	O
leading	O
to	O
an	O
over	O
-	O
estimation	O
of	O
the	O
species	O
’	O
impact	O
on	O
hemoglobin	B-GP
concentrations	O
.	O

Any	O
variations	O
in	O
the	O
prevalence	O
of	O
these	O
comorbid	O
conditions	O
in	O
different	O
regions	O
will	O
also	O
limit	O
the	O
generalizability	O
of	O
our	O
findings	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
shown	O
that	O
although	O
P	B-OG
.	I-OG
malariae	I-OG
is	O
responsible	O
for	O
a	O
small	O
proportion	O
of	O
malaria	B-DS
infections	B-DS
in	O
Papua	O
,	O
it	O
is	O
associated	O
with	O
appreciable	O
morbidity	O
and	O
also	O
mortality	O
.	O

This	O
verifies	O
the	O
clinical	O
relevance	O
of	O
infection	B-DS
with	O
non	O
-	O
falciparum	O
Plasmodium	B-OG
species	O
and	O
emphasizes	O
the	O
importance	O
of	O
attempting	O
to	O
eradicate	O
all	O
species	O
infecting	O
humans	B-OG
.	O

The	O
low	O
parasite	O
densities	O
,	O
high	O
incidence	O
of	O
asymptomatic	B-DS
disease	I-DS
and	O
the	O
longevity	O
of	O
P	B-DS
.	I-DS
malariae	I-DS
infections	I-DS
are	O
likely	O
to	O
present	O
significant	O
barriers	O
to	O
elimination	O
of	O
this	O
species	O
.	O

Supporting	O
Information	O

STROBE	O
checklist	O
.	O

(	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Database	O
in	O
tab	O
delimited	O
format	O
.	O

(	O
TXT	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

